WO2022239862A1 - 組成物およびその用途 - Google Patents
組成物およびその用途 Download PDFInfo
- Publication number
- WO2022239862A1 WO2022239862A1 PCT/JP2022/020222 JP2022020222W WO2022239862A1 WO 2022239862 A1 WO2022239862 A1 WO 2022239862A1 JP 2022020222 W JP2022020222 W JP 2022020222W WO 2022239862 A1 WO2022239862 A1 WO 2022239862A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- mir
- composition
- cells
- extracellular vesicles
- cell population
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 157
- 210000004027 cell Anatomy 0.000 claims abstract description 319
- 230000001172 regenerating effect Effects 0.000 claims abstract description 121
- 210000005087 mononuclear cell Anatomy 0.000 claims abstract description 60
- 239000012472 biological sample Substances 0.000 claims abstract description 36
- 206010052779 Transplant rejections Diseases 0.000 claims abstract description 34
- 230000000694 effects Effects 0.000 claims description 49
- 206010016654 Fibrosis Diseases 0.000 claims description 44
- 208000031225 myocardial ischemia Diseases 0.000 claims description 38
- 230000004761 fibrosis Effects 0.000 claims description 37
- 210000003556 vascular endothelial cell Anatomy 0.000 claims description 35
- 230000033115 angiogenesis Effects 0.000 claims description 34
- 102000004889 Interleukin-6 Human genes 0.000 claims description 29
- 108090001005 Interleukin-6 Proteins 0.000 claims description 29
- 210000004700 fetal blood Anatomy 0.000 claims description 29
- 229940100601 interleukin-6 Drugs 0.000 claims description 29
- 238000012258 culturing Methods 0.000 claims description 28
- 210000000130 stem cell Anatomy 0.000 claims description 28
- 102000036693 Thrombopoietin Human genes 0.000 claims description 27
- 108010041111 Thrombopoietin Proteins 0.000 claims description 27
- 230000035755 proliferation Effects 0.000 claims description 27
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 24
- 206010063837 Reperfusion injury Diseases 0.000 claims description 23
- 230000001939 inductive effect Effects 0.000 claims description 21
- 230000001737 promoting effect Effects 0.000 claims description 20
- 230000002792 vascular Effects 0.000 claims description 20
- 230000003511 endothelial effect Effects 0.000 claims description 19
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims description 18
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims description 18
- 210000002540 macrophage Anatomy 0.000 claims description 16
- 108091025616 miR-92a-2 stem-loop Proteins 0.000 claims description 16
- 210000005259 peripheral blood Anatomy 0.000 claims description 16
- 239000011886 peripheral blood Substances 0.000 claims description 16
- 108700014844 flt3 ligand Proteins 0.000 claims description 15
- 108091023084 miR-126 stem-loop Proteins 0.000 claims description 14
- 108091065272 miR-126-1 stem-loop Proteins 0.000 claims description 14
- 108091081187 miR-126-2 stem-loop Proteins 0.000 claims description 14
- 108091030790 miR-126-3 stem-loop Proteins 0.000 claims description 14
- 108091092317 miR-126-4 stem-loop Proteins 0.000 claims description 14
- 108091023108 miR-30e stem-loop Proteins 0.000 claims description 14
- 108091027549 miR-30e-1 stem-loop Proteins 0.000 claims description 14
- 108091029213 miR-30e-2 stem-loop Proteins 0.000 claims description 14
- 108091039792 miR-20b stem-loop Proteins 0.000 claims description 12
- 108091059199 miR-200a stem-loop Proteins 0.000 claims description 11
- 108091029956 miR-200a-1 stem-loop Proteins 0.000 claims description 11
- 108091088721 miR-200a-2 stem-loop Proteins 0.000 claims description 11
- 108091070312 miR-200a-3 stem-loop Proteins 0.000 claims description 11
- 230000001023 pro-angiogenic effect Effects 0.000 claims description 11
- 108091079658 miR-142-1 stem-loop Proteins 0.000 claims description 10
- 108091071830 miR-142-2 stem-loop Proteins 0.000 claims description 10
- 108091024038 miR-133a stem-loop Proteins 0.000 claims description 9
- 108091047757 miR-133a-1 stem-loop Proteins 0.000 claims description 9
- 108091057540 miR-133a-2 stem-loop Proteins 0.000 claims description 9
- 108091055152 miR-133a-3 stem-loop Proteins 0.000 claims description 9
- 108091079016 miR-133b Proteins 0.000 claims description 9
- 108091043162 miR-133b stem-loop Proteins 0.000 claims description 9
- -1 miR-146b-5p Proteins 0.000 claims description 9
- 108091090860 miR-150 stem-loop Proteins 0.000 claims description 9
- 108091091751 miR-17 stem-loop Proteins 0.000 claims description 9
- 108091074194 miR-181b-1 stem-loop Proteins 0.000 claims description 9
- 108091062762 miR-21 stem-loop Proteins 0.000 claims description 9
- 108091047189 miR-29c stem-loop Proteins 0.000 claims description 9
- 108091079151 miR-29c-1 stem-loop Proteins 0.000 claims description 9
- 108091084454 miR-302a stem-loop Proteins 0.000 claims description 9
- 108091039521 miR-363 stem-loop Proteins 0.000 claims description 9
- 108091036526 miR-633 stem-loop Proteins 0.000 claims description 9
- 101000610551 Homo sapiens Prominin-1 Proteins 0.000 claims description 8
- 102100040120 Prominin-1 Human genes 0.000 claims description 8
- 210000004369 blood Anatomy 0.000 claims description 8
- 239000008280 blood Substances 0.000 claims description 8
- 108091062895 miR-144 stem-loop Proteins 0.000 claims description 8
- 108091024530 miR-146a stem-loop Proteins 0.000 claims description 8
- 108091040069 miR-146a-1 stem-loop Proteins 0.000 claims description 8
- 108091081537 miR-146a-2 stem-loop Proteins 0.000 claims description 8
- 108091089775 miR-200b stem-loop Proteins 0.000 claims description 8
- 108091056309 miR-200b-1 stem-loop Proteins 0.000 claims description 8
- 108091026985 miR-200b-2 stem-loop Proteins 0.000 claims description 8
- 230000002401 inhibitory effect Effects 0.000 claims description 7
- 108091073704 let-7c stem-loop Proteins 0.000 claims description 7
- 108091081439 let-7c-1 stem-loop Proteins 0.000 claims description 7
- 108091062190 let-7c-2 stem-loop Proteins 0.000 claims description 7
- 108091064407 let-7c-3 stem-loop Proteins 0.000 claims description 7
- 108091058708 miR-103a-2 stem-loop Proteins 0.000 claims description 7
- 108091035155 miR-10a stem-loop Proteins 0.000 claims description 7
- 108091084882 miR-10a-1 stem-loop Proteins 0.000 claims description 7
- 108091027034 miR-148a stem-loop Proteins 0.000 claims description 7
- 108091092012 miR-199b stem-loop Proteins 0.000 claims description 7
- 108091030733 miR-205 stem-loop Proteins 0.000 claims description 7
- 108091048308 miR-210 stem-loop Proteins 0.000 claims description 7
- 108091068829 miR-210-1 stem-loop Proteins 0.000 claims description 7
- 108091069240 miR-210-2 stem-loop Proteins 0.000 claims description 7
- 108091061917 miR-221 stem-loop Proteins 0.000 claims description 7
- 108091047483 miR-24-2 stem-loop Proteins 0.000 claims description 7
- 108091088477 miR-29a stem-loop Proteins 0.000 claims description 7
- 108091063344 miR-30b stem-loop Proteins 0.000 claims description 7
- 108091055059 miR-30c stem-loop Proteins 0.000 claims description 7
- 108091072917 miR-30c-1 stem-loop Proteins 0.000 claims description 7
- 108091066131 miR-30c-2 stem-loop Proteins 0.000 claims description 7
- 108091085488 miR-30e-3 stem-loop Proteins 0.000 claims description 7
- 108091024082 miR-32 stem-loop Proteins 0.000 claims description 7
- 108091062587 miR-32-1 stem-loop Proteins 0.000 claims description 7
- 108091046551 miR-324 stem-loop Proteins 0.000 claims description 7
- 108091043953 miR-373 stem-loop Proteins 0.000 claims description 7
- 108091057331 miR-509 stem-loop Proteins 0.000 claims description 7
- 108091091880 miR-509-1 stem-loop Proteins 0.000 claims description 7
- 108091051359 miR-509-2 stem-loop Proteins 0.000 claims description 7
- 108091038238 miR-509-3 stem-loop Proteins 0.000 claims description 7
- 108091034121 miR-92a stem-loop Proteins 0.000 claims description 7
- 108091028159 miR-92a-1 stem-loop Proteins 0.000 claims description 7
- 108091049973 miR-92a-4 stem-loop Proteins 0.000 claims description 7
- 210000001185 bone marrow Anatomy 0.000 claims description 6
- 230000001332 colony forming effect Effects 0.000 claims description 6
- 108091031326 miR-15b stem-loop Proteins 0.000 claims description 6
- 108091057475 miR-29b-1 stem-loop Proteins 0.000 claims description 6
- 108091025088 miR-29b-2 stem-loop Proteins 0.000 claims description 6
- 108091043946 miR-29b-4 stem-loop Proteins 0.000 claims description 6
- 108091080274 miR-29b3 stem-loop Proteins 0.000 claims description 6
- 208000010125 myocardial infarction Diseases 0.000 claims description 6
- 102100025222 CD63 antigen Human genes 0.000 claims description 5
- 102100037904 CD9 antigen Human genes 0.000 claims description 5
- 101000934368 Homo sapiens CD63 antigen Proteins 0.000 claims description 5
- 208000030613 peripheral artery disease Diseases 0.000 claims description 4
- 210000004322 M2 macrophage Anatomy 0.000 claims description 3
- 208000032064 Chronic Limb-Threatening Ischemia Diseases 0.000 claims description 2
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 claims description 2
- 102100031706 Fibroblast growth factor 1 Human genes 0.000 claims description 2
- 206010034576 Peripheral ischaemia Diseases 0.000 claims description 2
- 230000001766 physiological effect Effects 0.000 abstract description 7
- 230000002829 reductive effect Effects 0.000 abstract description 7
- 238000000034 method Methods 0.000 description 58
- 239000002609 medium Substances 0.000 description 54
- 239000002679 microRNA Substances 0.000 description 44
- 108091070501 miRNA Proteins 0.000 description 42
- 230000006698 induction Effects 0.000 description 29
- 239000012528 membrane Substances 0.000 description 28
- 102100020880 Kit ligand Human genes 0.000 description 27
- 101710177504 Kit ligand Proteins 0.000 description 27
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 27
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 27
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 27
- 210000001519 tissue Anatomy 0.000 description 23
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 20
- 208000012947 ischemia reperfusion injury Diseases 0.000 description 19
- 238000012360 testing method Methods 0.000 description 19
- 102100020715 Fms-related tyrosine kinase 3 ligand protein Human genes 0.000 description 18
- 101710162577 Fms-related tyrosine kinase 3 ligand protein Proteins 0.000 description 18
- 238000011282 treatment Methods 0.000 description 15
- 239000000523 sample Substances 0.000 description 14
- 239000012679 serum free medium Substances 0.000 description 14
- 230000002107 myocardial effect Effects 0.000 description 13
- 230000002861 ventricular Effects 0.000 description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- 210000000056 organ Anatomy 0.000 description 12
- 230000037396 body weight Effects 0.000 description 11
- 230000005764 inhibitory process Effects 0.000 description 11
- 239000002245 particle Substances 0.000 description 11
- 239000000126 substance Substances 0.000 description 11
- 210000003954 umbilical cord Anatomy 0.000 description 11
- 239000000232 Lipid Bilayer Substances 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 10
- 230000002424 anti-apoptotic effect Effects 0.000 description 10
- 239000007640 basal medium Substances 0.000 description 10
- 230000004663 cell proliferation Effects 0.000 description 10
- 201000010099 disease Diseases 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 10
- 210000004271 bone marrow stromal cell Anatomy 0.000 description 9
- 238000012545 processing Methods 0.000 description 9
- 210000003289 regulatory T cell Anatomy 0.000 description 9
- 210000002966 serum Anatomy 0.000 description 9
- 241000700159 Rattus Species 0.000 description 8
- 238000001914 filtration Methods 0.000 description 8
- 210000000952 spleen Anatomy 0.000 description 8
- 108010052285 Membrane Proteins Proteins 0.000 description 7
- 230000002300 anti-fibrosis Effects 0.000 description 7
- 230000003510 anti-fibrotic effect Effects 0.000 description 7
- 210000004204 blood vessel Anatomy 0.000 description 7
- 239000006285 cell suspension Substances 0.000 description 7
- 238000005119 centrifugation Methods 0.000 description 7
- 239000003636 conditioned culture medium Substances 0.000 description 7
- 210000001808 exosome Anatomy 0.000 description 7
- 238000000605 extraction Methods 0.000 description 7
- 238000000684 flow cytometry Methods 0.000 description 7
- 230000012010 growth Effects 0.000 description 7
- 238000002955 isolation Methods 0.000 description 7
- 238000010899 nucleation Methods 0.000 description 7
- 238000004904 shortening Methods 0.000 description 7
- 230000001629 suppression Effects 0.000 description 7
- 101000993347 Gallus gallus Ciliary neurotrophic factor Proteins 0.000 description 6
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 6
- 210000000805 cytoplasm Anatomy 0.000 description 6
- 230000001086 cytosolic effect Effects 0.000 description 6
- 208000028867 ischemia Diseases 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 239000002243 precursor Substances 0.000 description 6
- 239000012134 supernatant fraction Substances 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 description 5
- 102100022338 Integrin alpha-M Human genes 0.000 description 5
- 206010027727 Mitral valve incompetence Diseases 0.000 description 5
- 230000000735 allogeneic effect Effects 0.000 description 5
- 239000000427 antigen Substances 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 239000012228 culture supernatant Substances 0.000 description 5
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 102000018697 Membrane Proteins Human genes 0.000 description 4
- 102100033344 Programmed cell death 6-interacting protein Human genes 0.000 description 4
- 238000010162 Tukey test Methods 0.000 description 4
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000010261 cell growth Effects 0.000 description 4
- 230000004069 differentiation Effects 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 238000004020 luminiscence type Methods 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 208000005907 mitral valve insufficiency Diseases 0.000 description 4
- 238000004393 prognosis Methods 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 230000001954 sterilising effect Effects 0.000 description 4
- 238000007492 two-way ANOVA Methods 0.000 description 4
- 229920001342 Bakelite® Polymers 0.000 description 3
- 101000836492 Dictyostelium discoideum ALG-2 interacting protein X Proteins 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 101001134621 Homo sapiens Programmed cell death 6-interacting protein Proteins 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 238000011316 allogeneic transplantation Methods 0.000 description 3
- 230000001640 apoptogenic effect Effects 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 239000002458 cell surface marker Substances 0.000 description 3
- 210000000038 chest Anatomy 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 230000001506 immunosuppresive effect Effects 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 239000004816 latex Substances 0.000 description 3
- 229920000126 latex Polymers 0.000 description 3
- 210000005246 left atrium Anatomy 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 210000002751 lymph Anatomy 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 239000011148 porous material Substances 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 230000008439 repair process Effects 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 241001125840 Coryphaenidae Species 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 238000000018 DNA microarray Methods 0.000 description 2
- 241000283086 Equidae Species 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 108090000174 Interleukin-10 Proteins 0.000 description 2
- 108090000978 Interleukin-4 Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 206010029113 Neovascularisation Diseases 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 241000283203 Otariidae Species 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- 210000004241 Th2 cell Anatomy 0.000 description 2
- 230000001464 adherent effect Effects 0.000 description 2
- 238000003450 affinity purification method Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 230000003416 augmentation Effects 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000010293 colony formation assay Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000002592 echocardiography Methods 0.000 description 2
- 210000001163 endosome Anatomy 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 102000058223 human VEGFA Human genes 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 208000023589 ischemic disease Diseases 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 210000005240 left ventricle Anatomy 0.000 description 2
- 210000003141 lower extremity Anatomy 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 210000003593 megakaryocyte Anatomy 0.000 description 2
- 238000001000 micrograph Methods 0.000 description 2
- 230000002297 mitogenic effect Effects 0.000 description 2
- 108091027963 non-coding RNA Proteins 0.000 description 2
- 102000042567 non-coding RNA Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical group 0.000 description 2
- 230000034918 positive regulation of cell growth Effects 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000013587 production medium Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 1
- 101710087718 ALG-2 interacting protein X Proteins 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 101710163595 Chaperone protein DnaK Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 102000018932 HSP70 Heat-Shock Proteins Human genes 0.000 description 1
- 108010027992 HSP70 Heat-Shock Proteins Proteins 0.000 description 1
- 101710178376 Heat shock 70 kDa protein Proteins 0.000 description 1
- 101710152018 Heat shock cognate 70 kDa protein Proteins 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 101000738354 Homo sapiens CD9 antigen Proteins 0.000 description 1
- 206010020675 Hypermetropia Diseases 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 108091030146 MiRBase Proteins 0.000 description 1
- 108700011259 MicroRNAs Proteins 0.000 description 1
- 108091028066 Mir-126 Proteins 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 101710198445 Programmed cell death 6-interacting protein Proteins 0.000 description 1
- 230000018199 S phase Effects 0.000 description 1
- YIQKLZYTHXTDDT-UHFFFAOYSA-H Sirius red F3B Chemical compound C1=CC(=CC=C1N=NC2=CC(=C(C=C2)N=NC3=C(C=C4C=C(C=CC4=C3[O-])NC(=O)NC5=CC6=CC(=C(C(=C6C=C5)[O-])N=NC7=C(C=C(C=C7)N=NC8=CC=C(C=C8)S(=O)(=O)[O-])S(=O)(=O)[O-])S(=O)(=O)O)S(=O)(=O)O)S(=O)(=O)[O-])S(=O)(=O)[O-].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+] YIQKLZYTHXTDDT-UHFFFAOYSA-H 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 210000000628 antibody-producing cell Anatomy 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 210000002565 arteriole Anatomy 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000001746 atrial effect Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 238000009583 bone marrow aspiration Methods 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 230000005757 colony formation Effects 0.000 description 1
- 238000004624 confocal microscopy Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000003205 diastolic effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 235000021186 dishes Nutrition 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 210000002288 golgi apparatus Anatomy 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 201000006318 hyperopia Diseases 0.000 description 1
- 230000004305 hyperopia Effects 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 210000004263 induced pluripotent stem cell Anatomy 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 210000005061 intracellular organelle Anatomy 0.000 description 1
- 238000011694 lewis rat Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004880 lymph fluid Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 1
- 108091031832 miR-126b stem-loop Proteins 0.000 description 1
- 210000004088 microvessel Anatomy 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 230000009707 neogenesis Effects 0.000 description 1
- 238000012758 nuclear staining Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 210000004786 perivascular cell Anatomy 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 1
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000010410 reperfusion Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000004017 serum-free culture medium Substances 0.000 description 1
- 229960002078 sevoflurane Drugs 0.000 description 1
- DFEYYRMXOJXZRJ-UHFFFAOYSA-N sevoflurane Chemical compound FCOC(C(F)(F)F)C(F)(F)F DFEYYRMXOJXZRJ-UHFFFAOYSA-N 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 239000012929 tonicity agent Substances 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 210000005167 vascular cell Anatomy 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/51—Umbilical cord; Umbilical cord blood; Umbilical stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
Definitions
- the present invention relates to compositions and uses thereof.
- an object of the present invention is to provide cell-derived extracellular vesicles that reduce graft rejection and have physiological activity.
- composition of the present invention contains extracellular vesicles of regenerative cell populations or cultures thereof derived from mononuclear cells derived from biological samples.
- the present invention provides a composition for use in treating ischemic heart disease, comprising:
- the composition is the composition of the present invention.
- the present invention provides a composition for use in promoting proliferation of vascular endothelial cells,
- the composition is the composition of the present invention.
- the present invention provides a composition for use in inducing angiogenesis, comprising:
- the composition is the composition of the present invention.
- the present invention provides a composition for use in suppressing fibrosis,
- the composition is the composition of the present invention.
- extracellular vesicles with reduced graft rejection and physiological activity can be provided.
- FIG. 1 is a graph showing the particle size, the amount produced per cell, and the average size of extracellular vesicles in Example 1.
- FIG. 2 is an electron microscope image showing the structure of RAC-derived extracellular vesicles in Example 1.
- FIG. 3 is a histogram showing the expression of markers in Example 1.
- FIG. 4 is a graph showing proliferation of HUVEC cells in Example 1.
- FIG. 5 is a photograph and a graph showing growth areas of HUVEC cells in Example 1.
- FIG. 6 is a graph showing the expression level of miRNA in Example 1.
- FIG. FIG. 7 is a photograph showing an echogram in Example 1, and a graph showing the ejection fraction and left ventricular inner diameter shortening ratio.
- FIG. 8 is a graph showing severity of mitral valve regurgitation and left ventricular end-systolic volume in Example 1.
- FIG. 9 is a graph and photographs showing the degree of fibrosis in Example 1.
- FIG. 10 is a graph showing the expression level of miRNA in Example 1.
- FIG. 11 is a photograph showing blood vessels in infarcted myocardial tissue in Example 1.
- FIG. 12 is a graph showing the expression level of miRNA in Example 1.
- FIG. 13 is a photograph showing a fluorescent image of infarcted myocardial tissue in Example 1.
- FIG. 14 is a photograph and a graph showing the luminescence intensity of infarcted myocardial tissue in Example 1.
- FIG. 15 is a graph showing rat body weight and spleen weight in Example 1.
- FIG. 15 is a graph showing rat body weight and spleen weight in Example 1.
- FIG. 16 is a graph showing the percentages of CD3-positive cells, CD4-positive cells, CD8-positive cells, regulatory T cells and CD11b/c-positive cells in Example 1.
- FIG. 17 is a graph showing the percentages of CD3-positive cells, CD4-positive cells, CD8-positive cells, TNK, iNK, regulatory T cells and CD11b/c-positive cells in Example 1.
- FIG. 18 is a graph showing the expression level of miRNA in Example 1.
- FIG. 19 is a graph showing the number of cells in Example 2.
- FIG. 20 is a graph showing the results of EPC-CFA assay in Example 2.
- FIG. 21 is a graph showing the expression level of miRNA in Example 3.
- FIG. 22 is a graph showing the expression level of miRNA in Example 3.
- a "biological sample” is a sample derived from a living organism, and means a sample from which cells that constitute the living organism can be extracted or isolated.
- mononuclear cell means a cell with a round nucleus contained in peripheral blood, bone marrow, cord blood, or the like.
- the mononuclear cells include, for example, lymphocytes, monocytes, macrophages, vascular endothelial progenitor cells, hematopoietic stem cells and the like. Said mononuclear cells may further comprise CD34 and/or CD133 positive cells.
- extracellular vesicle means a vesicle having a membrane that is secreted from cells.
- the extracellular vesicles are generally considered to be formed within the endosome of the cell from which they are derived and then released outside the cell.
- the extracellular vesicle usually includes a lipid bilayer membrane and a lumen, and the lumen has a structure surrounded by the lipid bilayer membrane.
- the lipid bilayer membrane contains lipids derived from the cell membrane of the cell from which it is derived.
- the lumen then contains cytoplasm from the cells from which it originates.
- the extracellular vesicles are classified into, for example, exosomes, microvesicles (MV), apoptotic bodies, etc., according to their size and/or surface markers.
- regenerative cell population means a cell population containing cells with regenerative function.
- the regenerative function means a function of repairing or improving a tissue, an organ, or a function of an organ, and any one function may be performed.
- Specific examples of the regenerative function include vascular endothelial cell proliferation activity and/or angiogenesis promoting activity.
- a "cell population” means a cell preparation containing desired cells or a composition containing desired cells. Therefore, the cell population can also be referred to herein as, for example, a cell preparation or composition.
- the ratio of desired cells to all cells (hereinafter also referred to as “purity”) can be quantified, for example, as the ratio of cells expressing one or more markers expressing desired cells.
- the purity is, for example, the percentage in viable cells. The purity can be measured, for example, by flow cytometry, immunohistochemistry, in situ hybridization, and the like.
- the purity of the cell preparation is, for example, 50% or higher, 55% or higher, 60% or higher, 65% or higher, 70% or higher, 75% or higher, 80% or higher, 85% or higher, 90% or higher , 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, 97% or more, 98% or more, or 99% or more.
- culture means a product containing cells obtained by culturing a subject cell and/or a culture medium of said cells.
- umbilical cord means a white tubular tissue that connects the fetus and placenta.
- the origin of the "umbilical cord” is not particularly limited. , an umbilical cord of a primate mammal, more preferably a human umbilical cord.
- cord blood means fetal blood contained in the umbilical cord.
- miRNA means non-coding RNA with a base length of about 18 to about 25 bases.
- the miRNA can also be referred to as “microRNA”, “miR”, and the like.
- miRNA precursor means a transcript containing non-coding RNA originating from genomic DNA and containing one or more miRNA sequences. Said miRNA precursors can also be referred to as “pri-miRNA” (pri-miRNA), or “pre-miRNA” (pre-miRNA).
- pri-miRNA pri-miRNA
- pre-miRNA pre-miRNA
- the miRNA precursor usually has a hairpin structure and contains the base sequence of a mature miRNA.
- mir-X refers to the precursor of miRNA with number X
- miR-X refers to the mature form of miRNA with number X (miRNA).
- two miRNAs are denoted with the suffix “-3p” or “-5p” when they originate from opposite arms of the same miRNA precursor.
- miR-X refers to both -3p and -5p miRNAs when the miRNA precursor contains two miRNAs.
- miRNA with the low expression level is denoted by an asterisk after the name. is used.
- Information such as the base sequences of each “mir-X” and “miR-X” can be referred to miRBase (http://www.mirbase.org/).
- cell proliferation promotion means that the proliferation of target cells is significantly promoted.
- the target cell is a desired cell.
- Said facilitation may also be referred to as enhancement, augmentation, or increase.
- stimulation of cell growth means that a group treated with a test substance is compared with a control group not treated with the test substance or a control group treated with a substance having no cell growth-promoting activity. means that the proliferation of the target cells is significantly promoted. Therefore, in the present specification, even if the cell proliferation activity is reduced in the control group compared to the control group at the start of the test, the cell proliferation of the target cells is significant compared to the control group. , it can be said that "stimulation of cell growth” has occurred.
- the cell proliferation activity can be measured, for example, according to Example 1 described later.
- promoted angiogenesis means that the formation or proliferation of blood vessels is significantly promoted. Said facilitation may also be referred to as enhancement, augmentation, or increase.
- promoting angiogenesis means that the test substance-treated group is compared with a control group that is not treated with the test substance or a control group that is treated with a substance having no angiogenesis-promoting activity. , means that the angiogenesis or hyperplasia is significantly promoted.
- angiogenesis-promoting activity can be measured, for example, according to Example 1 described later.
- fibrosis suppression means that fibrosis in a subject is significantly suppressed. Said inhibition may also be referred to as reduction, reduction, inhibition, inhibition or prevention.
- fibrosis inhibition means that a group treated with a test substance compares with a control group not treated with the test substance or a control group treated with a substance having no fibrosis-inhibiting activity. , meaning that the subject's fibrosis is significantly suppressed. Therefore, in the present specification, even if fibrosis is suppressed in the control group compared to the control group at the start of the test, fibrosis in the subject is significantly suppressed compared to the control group. If so, it can be said that "fibrosis inhibition” has occurred.
- the fibrosis-suppressing activity can be measured, for example, according to Example 1 described later.
- graft rejection refers to cell, tissue, organ, or organ transplantation to eliminate grafts induced in the host due to differences in major histocompatibility antigens. It means the host reaction to Said graft rejection can also be referred to as “alloreaction” or “allograft rejection” when within the same species.
- the graft rejection can also be referred to as “xenograft rejection” in the case of xenograft rejection.
- the "graft rejection” can be measured, for example, according to Example 1 described later.
- “suppression of graft rejection” or “suppression of immune rejection” means that graft rejection or immune rejection is significantly suppressed. Said inhibition may also be referred to as reduction, reduction, inhibition, inhibition or prevention.
- the “inhibition of graft rejection” means that the graft rejection is significantly inhibited in the group treated with the test substance compared to the control group treated with the substance that induces graft rejection. means that As a specific example, when examining the graft rejection of the extracellular vesicles, the group treated with the extracellular vesicles is compared with a control group treated with the cells derived from the extracellular vesicles. When graft rejection is significantly inhibited, it can be said that the extracellular vesicle inhibits graft rejection.
- the "graft rejection” can be measured, for example, according to Example 1 described later.
- extraction means a state in which a specific component is more concentrated than before extraction. For this reason, said extraction can also be referred to as concentration or enrichment. Said “extraction” can be carried out, for example, by obtaining at least one concentration step.
- isolated means a state in which a specific component has been identified and separated, and/or recovered from the component in its natural state. Said “isolation” can be carried out, for example, by obtaining at least one purification step.
- positive (+) means a negative control cell that does not express the antigen or an antibody that does not react with the antigen by an analysis method such as flow cytometry that is detected using an antigen-antibody reaction. It means that a high signal is detected compared to the control reaction.
- negative (-) means that an equivalent or lower signal is detected compared to a negative control reaction using a negative control cell that does not express the antigen or an antibody that does not react with the antigen. means.
- treatment means therapeutic treatment and/or prophylactic treatment.
- treatment means treating, curing, preventing, arresting, ameliorating, ameliorating a disease, condition, or disorder, or halting, arresting, reducing, or delaying the progression of a disease, condition, or disorder. do.
- prevention means reducing the likelihood of developing a disease or condition or delaying the onset of a disease or condition.
- the “treatment” may be, for example, treatment of a patient who develops the target disease, or treatment of a model animal of the target disease.
- the term "effective dose” means an amount sufficient to obtain a therapeutic effect for the disease when administered to a patient with the disease.
- subject means an animal or an animal-derived cell, tissue, or organ, and is particularly used to include humans.
- Said animal means both human and non-human animals.
- non-human animals include mammals such as mice, rats, rabbits, dogs, cats, cows, horses, pigs, monkeys, dolphins, and sea lions.
- the present invention provides cell-derived extracellular vesicles with reduced graft rejection and bioactivity, or compositions comprising the same.
- Extracellular vesicles of the present invention are extracellular vesicles of regenerative cell populations or cultures thereof derived from mononuclear cells derived from biological samples.
- Compositions of the invention also include extracellular vesicles of regenerative cell populations or cultures thereof derived from mononuclear cells from biological samples. Since the extracellular vesicles or composition of the present invention suppresses the above-mentioned graft rejection and is derived from the above-mentioned regenerative cell population, they have physiological activities such as vascular endothelial cell growth promotion activity and angiogenesis promotion activity. have Therefore, the extracellular vesicles or composition of the present invention can be suitably used for treating ischemic heart disease or improving prognosis, for example, as described later.
- the regenerative cell population is a cell population induced from mononuclear cells derived from the biological sample.
- the regenerative cell population includes, for example, cells with regenerative function inducible from the mononuclear cells.
- the cells having regenerative function include, for example, vascular endothelial progenitor cells, anti-inflammatory macrophages, and the like, and may also include Th2 cells, regulatory T cells (Treg), and the like.
- the vascular endothelial progenitor cells and the anti-inflammatory macrophages for example, have angiogenesis-promoting activity and anti-inflammatory activity as the regeneration function, so that at an inflammatory site such as an ulcer, not only angiogenesis but also inflammation It is extremely useful in that it can be suppressed.
- the regenerative cell population contains one or more types of cells having the regenerative function.
- the vascular endothelial progenitor cells are cells that have the ability to differentiate into vascular endothelial cells.
- the vascular endothelial progenitor cells can be identified using cell surface markers such as CD34, CD133, KDR (Kinase insert domain receptor, CD309), and CD105.
- the vascular endothelial progenitor cells may be further classified according to the degree of differentiation.
- the vascular endothelial progenitor cells can be further classified into differentiated EPC colony cells and undifferentiated EPC colony cells.
- the differentiated EPC colony cells mainly contain cells with a diameter of 20 to 50 ⁇ m (CFU-large cell-like EC, hereinafter also referred to as “large EPC colony”).
- the undifferentiated EPC colony cells mainly contain cells with a diameter of 20 ⁇ m or less (CFU-small cell-like EC, hereinafter also referred to as “small EPC colony”).
- the small EPC colonies that appear at an early stage can be said to be EPC colonies at an early stage of differentiation with excellent proliferative ability, and the large EPC colonies that appear at a later stage are vascular cells. It can be said to be an EPC colony at a late stage of differentiation with excellent development (neogenesis) (see, for example, Masuda H. et al., Circulation Research, 109: 20-37 (2011)).
- the differentiated EPC colony cells are, for example, superior in regenerative functions such as angiogenesis or repair compared to the undifferentiated EPC colony cells. Therefore, the vascular endothelial progenitor cells are differentiated EPC colony forming cells. Preferably.
- the anti-inflammatory macrophage is a type of macrophage that secretes anti-inflammatory cytokines (IL-10, IL-4) and the like, and is a cell that contributes to angiogenesis or repair. Said anti-inflammatory macrophages can be identified using cell surface markers such as, for example, CD206, CD163, CD169.
- the anti-inflammatory macrophages are preferably M2 macrophages because they are excellent in regenerative functions such as angiogenesis or repair.
- the proportion of cells having regenerative function in all cells of the regenerative cell population is not particularly limited, and is, for example, 10% or more, 15% or more, 20% or more, 25% or more, 30% or more, 35% or more. , 40% or more, 45% or more, 50% or more, 55% or more, 60% or more, 65% or more, 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 96 % or greater, 97% or greater, 98% or greater, or 99% or greater.
- the proportion of cells can be calculated, for example, by measuring the proportion of target cell surface marker-positive cells using the cell surface marker having regenerative function. Said measurement can be carried out, for example, using a flow cytometry method.
- the ratio of the cells having a regenerative function to the total cells of the regenerative cell population is, for example, usually twice the ratio of the corresponding cells having a regenerative function in the mononuclear cells derived from the biological sample, Preferably, the increase is four times or more.
- the ratio of the cells having a regenerative function to the total cells of the regenerative cell population is, for example, the ratio of CD34-positive cells and CD206 It can be calculated as a total percentage of the percentage of positive cells.
- the biological sample used for inducing the regenerative cell population may be a biological sample containing the mononuclear cells. Said mononuclear cells are abundant in blood and lymph.
- said biological sample may be a tissue, organ and/or organ, including blood and/or lymph vessels, or may be blood and/or lymph. Specific examples of the biological sample include bone marrow; blood such as umbilical cord blood and peripheral blood; lymph fluid; and the like.
- the biological sample may be a biological sample collected from a subject of administration, treatment, or treatment of the extracellular vesicles and/or composition of the present invention (hereinafter collectively referred to as "administration subject"). It may be a biological sample collected from a subject other than the subject. It is desirable to use a biological sample collected from a person other than the administration subject from the viewpoint of not being subject to restrictions during preparation.
- the regenerative cell population may be cells (allogeneic cells) derived from a biological sample collected from a subject other than the subject of administration, or derived from a biological sample collected from the subject of administration, as described in the examples below. cells (autologous cells).
- the extracellular vesicles can be suitably prepared even using a biological sample collected from a person other than the administration subject, because the graft rejection reaction is suppressed.
- the extracellular vesicles exert therapeutic effects without being eliminated by immune rejection or the like, for example.
- the extracellular vesicles can be prepared, for example, as an off-the-shelf formulation.
- the method for preparing the biological sample is not particularly limited, and can be set appropriately according to the type of the biological sample, for example.
- the biological sample when the biological sample is bone marrow, the biological sample can be obtained, for example, by performing bone marrow aspiration on the subject.
- the biological sample when the biological sample is peripheral blood, the biological sample can be obtained by collecting venous blood, for example.
- the biological sample is umbilical cord blood, the biological sample can be obtained, for example, by isolating the umbilical cord and then collecting the blood in the umbilical cord.
- the method for isolating mononuclear cells from the biological sample can be carried out according to a method commonly practiced in the art. It can be carried out by separating the mononuclear cells from other components using a nuclear cell separation solution.
- a method for inducing the cells having the regenerative function from the mononuclear cells derived from the biological sample can be carried out, for example, by a known method depending on the type of the cells having the regenerative function.
- the induction method includes, for example, culturing the mononuclear cells in the presence of SCF, IL-6, FLT3L, TPO, and/or VEGF.
- the induction method includes, for example, culturing the mononuclear cells in the presence of IL-10, IL-4, M-CSF and/or G-CSF. It can be implemented by
- the induction method is preferably a method capable of inducing both the vascular endothelial progenitor cells and the anti-inflammatory macrophages from the mononuclear cells.
- the induction method for example, reference can be made to the induction method described in International Publication No. 2014/051154.
- the regenerative cell population can induce cells having the regenerative function, including extracellular vesicles having the pro-angiogenic activity and the anti-inflammatory activity.
- IL-6 interleukin-6
- FMS-like tyrosine kinase 3 ligand Flt3L
- TPO thrombopoietin
- VEGF vascular endothelial growth factor
- the mononuclear cells to be cultured may be a desired cell population obtained by selecting a desired cell population from the biological sample-derived mononuclear cells, or the biological sample-derived mononuclear cells themselves. may be used.
- mononuclear cells to be cultured mononuclear cells obtained without sorting CD34 and/or CD133 positive cells (unsorted mononuclear cells) are preferably used.
- the differentiated EPC colony-forming cells are increased (amplified) compared to, for example, the case of using mononuclear cells sorted as CD34-positive cells, and the A cell population with increased (amplified) anti-inflammatory macrophages and increased (amplified) anti-inflammatory Th2 cells and regulatory T cells is formed. Therefore, by using the unsorted mononuclear cells, for example, it is possible to obtain, as the regenerative cell population, a cell population enriched with cells having the regenerative function. It is possible to obtain extracellular vesicles with excellent physiological activities such as proliferation-promoting activity, angiogenesis-promoting activity, fibrosis-suppressing activity, graft rejection-suppressing activity, and immunosuppressive activity.
- the SCF is a glycoprotein with a molecular weight of about 30,000 consisting of 248 amino acids. Said SCF is produced in soluble and membrane-bound forms by alternative splicing.
- the SCF used for the culture may be any type of SCF as long as it is useful for culturing regenerative cell populations such as EPCs. A soluble form is preferred.
- the origin of the SCF is not particularly limited, it is preferably a recombinant, and particularly preferably a human recombinant, because it is expected to be supplied stably. Said human recombinant SCF is commercially available.
- the concentration of SCF in the medium can be set according to the type of SCF, and is not particularly limited as long as it is useful for culturing regenerative cell populations such as EPCs.
- the concentration of SCF in the medium is, for example, 10 to 1000 ng/ml, preferably 50 to 500 ng/ml, more preferably about 100 ng/ml. be.
- the IL-6 is a glycoprotein with a molecular weight of about 21,000 that was isolated as a factor that induces the terminal differentiation of B cells into antibody-producing cells. It is known to be involved in the phase reaction, etc.
- the origin of IL-6 is not particularly limited, but a recombinant is preferable, and a human recombinant is particularly preferable, since a stable supply is expected. Said human recombinant IL-6 is commercially available.
- the concentration of IL-6 in the medium varies depending on the type of IL-6 used, but is not particularly limited as long as it is useful for culturing regenerative cell populations such as EPCs.
- the concentration of IL-6 in the medium is, for example, 1 to 500 ng/ml, preferably 5 to 100 ng/ml, more preferably , about 20 ng/ml.
- the Flt3L is known as a receptor tyrosine kinase ligand that plays an important role in the control of early hematopoiesis.
- Flt3L is known to be a product of several alternative splicings, and is reported to stimulate the proliferation of hematopoietic stem cells.
- the Flt3L may be any type of Flt3L as long as it is useful for culturing regenerative cell populations such as EPCs.
- the origin of Flt3L is not particularly limited, it is preferably a recombinant, particularly preferably a human recombinant, because it is expected to be supplied stably. Said human recombinant Flt3L is commercially available.
- the concentration of Flt3L in the medium varies depending on the type of Flt3L used, but is not particularly limited as long as it is useful for culturing regenerative cell populations such as EPCs.
- the concentration of Flt3L in the medium is, for example, 10 to 1000 ng/ml, preferably 50 to 500 ng/ml, more preferably about 100 ng/ml. be.
- the TPO is a type of hematopoietic cytokine, and is known to act specifically on the process of megakaryocyte production from hematopoietic stem cells and promote the production of megakaryocytes.
- the origin of the TPO is not particularly limited, it is preferably a recombinant, and particularly preferably a human recombinant, because it is expected to be supplied stably.
- Said human recombinant TPO is commercially available.
- the concentration of TPO in the medium varies depending on the type of TPO used, but is not particularly limited as long as it is useful for culturing regenerative cell populations such as EPCs.
- the concentration of TPO in the medium is, for example, 1 to 500 ng/ml, preferably 5 to 100 ng/ml, more preferably about 20 ng/ml. be.
- the VEGF is a growth factor that specifically acts on EPCs and is known to be produced mainly in perivascular cells. Said VEGF produces several types of VEGF proteins with different sizes by alternative splicing.
- the VEGF may be any type of VEGF, preferably VEGF165, as long as it allows colony formation of the EPCs contained in the regenerative cell population.
- the origin of the VEGF is not particularly limited, it is preferably a recombinant, particularly preferably a human recombinant, because it is expected to be supplied stably. Said human recombinant VEGF is commercially available.
- the concentration of VEGF in the medium varies depending on the type of VEGF used, and is not particularly limited as long as it is useful for culturing regenerative cell populations such as EPCs.
- the concentration of VEGF in the medium is, for example, about 5-500 ng/ml, preferably about 20-100 ng/ml, more preferably about 50 ng/ml.
- factors derived from animals of the same or different species as the animal from which the mononuclear cells are derived are used, and factors derived from the same species of animals are preferably used.
- a regenerative cell population suitable for allogeneic transplantation such as allogeneic transplantation and extracellular vesicles derived therefrom can be obtained.
- extracellular vesicles suitable for allogeneic transplantation can be obtained by using mononuclear cells derived from the administration subject.
- the obtained regenerative cell population and extracellular vesicles derived therefrom are susceptible to infection at the time of administration, etc. Can reduce risk and rejection.
- the medium used for the culture may be prepared by dissolving the various factors in a basal medium to a predetermined concentration, or a concentrated solution (stock solution) containing the various factors may be prepared in advance and added to the desired medium. You may prepare by diluting to a predetermined density
- the medium used for the culture may be prepared by dissolving various factors necessary for a commercially available basal medium to a predetermined concentration and then sterilizing by filtration sterilization or the like, or a stock solution sterilized by filtration sterilization or the like. may be prepared by aseptically adding and diluting into commercially available basal media.
- the sterilization by filtration can be performed according to a method commonly practiced in the art, and can be performed using, for example, a Millipore filter with a pore size of 0.22 ⁇ m or 0.45 ⁇ m.
- a basal medium commonly used in the art can be used, for example, a basal medium known as a medium for proliferation of hematopoietic stem cells can be used.
- the basal medium may be a serum-containing medium or a serum-free medium, ie a serum-free medium.
- a serum-free medium is used as the medium and/or the basal medium, thereby efficiently culturing (inducing) the regenerative cell population from the mononuclear cells. It can be induced (amplified) well. Therefore, the medium is preferably a serum-free medium.
- the medium or basal medium include DMEM, MEM, IMDM and the like.
- the medium contains at least one factor, preferably three or more factors, more preferably all factors selected from the group consisting of SCF, IL-6, FLT3L, TPO, and VEGF. Therefore, the medium used for the culture contains, for example, any of the following.
- the medium more preferably contains SCF, IL-6, FLT3L, TPO, and VEGF.
- the medium more preferably comprises about 50 ng/ml VEGF, about 100 ng/ml SCF, about 20 ng/ml IL-6, 100 ng/ml FLT3L, and about 20 ng/ml TPO.
- the mononuclear cell culture using the medium containing the various factors can be performed by adding the cell suspension containing the mononuclear cells to the medium containing the various factors.
- a bodily fluid containing the mononuclear cells for example, bone marrow fluid, umbilical cord blood, peripheral blood
- the conditions for culturing the mononuclear cells are not particularly limited, and the conditions usually used in the art can be used. As a specific example, the culture conditions are, for example, culturing at 37° C. for 7 days or more (eg, 10 days or more) in a 5% CO 2 atmosphere.
- the concentration of the mononuclear cells in the medium is not particularly limited as long as it enables the culture of regenerative cell populations such as EPCs.
- the concentration (seeding density) of the mononuclear cells in the medium is, for example, about 0.5 to 10 ⁇ 10 5 cells/ml, more preferably about 1 to 5 ⁇ 10 5 cells/ml, still more preferably about 3-4 ⁇ 10 5 cells/ml.
- the culture of the regenerative cell population may be a culture obtained by inducing the regenerative cell population from the mononuclear cells, or a culture obtained by culturing the induced regenerative cell population.
- the medium and culture conditions for the regenerative cell population are not particularly limited, and for example, the description of the medium and culture conditions for the mononuclear cells can be used.
- the medium for the regenerative cell population can be, for example, a medium obtained by adding serum, preferably human-derived serum, to the basal medium.
- the origin of the serum may be the same as or different from that of the regenerative cell population, but is preferably the same.
- the serum may contain the extracellular vesicles. Therefore, when the serum is added to the basal medium, it is preferable to use serum from which extracellular vesicles have been removed.
- the extracellular vesicle-depleted serum is commercially available.
- the serum concentration is, for example, 1 to 20 (v/v)%, preferably 1 to 10 (v/v)%.
- Culturing of the regenerative cell population can be performed by adding a cell suspension containing the regenerative cell population to a medium for the regenerative cell population.
- the conditions for culturing the regenerative cell population are not particularly limited, and the conditions usually used in the art can be used.
- the culture conditions are, for example, culturing at 37° C. for 1 to 10 days (eg, 1 to 2 days) in a 5% CO 2 atmosphere.
- the concentration (seeding density) of the regenerative cell population in the medium is not particularly limited as long as the regenerative cell population can be cultured.
- the concentration (seeding density) of the regenerative cell population in the medium is, for example, about 1 ⁇ 10 4 to 1 ⁇ 10 7 cells/ml, more preferably about 1 ⁇ 10 5 to 1 ⁇ 10 6 cells/ml. ml, more preferably about 5 ⁇ 10 5 cells/ml.
- Said extracellular vesicles are secreted from the cell from which they are derived, as described above.
- said extracellular vesicles may be isolated or extracted from said regenerative cell population or culture thereof.
- the extracellular vesicles When extracted or isolated from the regenerative cell population, the extracellular vesicles are, for example, disrupted the regenerative cell population to release intracellular extracellular vesicles of the regenerative cell population, After separating the soluble fraction from the resulting suspension, the soluble fraction can be isolated or extracted by subjecting the soluble fraction to a method for isolating or extracting extracellular vesicles.
- the method for isolating or extracting the extracellular vesicles can be performed according to a method commonly practiced in the art, for example, a method using centrifugation, It can be performed by a membrane protein derived from a regenerative cell population, an affinity purification method using the membrane protein, filtration using a porous membrane such as a filter, or the like.
- a membrane filter for example, a commercially available membrane filter can be used, and as a specific example, a membrane filter with a pore size of 0.22 ⁇ m (manufactured by Millipore) can be used.
- Membrane proteins of the extracellular vesicles are described below.
- a commercially available kit may be used for the isolation or extraction of the extracellular vesicles, and as a specific example, the qEv isolation kit (manufactured by Izon Sciences) can be used.
- the centrifugation conditions may be conditions that allow the extracellular vesicles to be precipitated. ⁇ 180,000 xg for 20-60 minutes.
- the temperature during the centrifugation is, for example, 0 to 10°C, preferably 0 to 4°C.
- the culture is, for example, composed of the regenerative cell population and its medium (conditioned medium or culture supernatant).
- said extracellular vesicles when isolated from said culture, may be isolated or extracted from said regenerative cell population or said conditioned medium, or both said regenerative cell population and said conditioned medium. can be separated from
- the method for separating the regenerative cell population and the conditioned medium from the culture can be performed according to a method commonly practiced in the art, for example, filter filtration, centrifugation, etc. .
- the extracellular vesicles can be isolated or extracted in the same manner as the extraction or isolation from the regenerative cell population described above.
- the method for isolating or extracting the extracellular vesicles is, for example, a method using centrifugation, a membrane protein derived from a regenerative cell population present in the membrane of the extracellular vesicles, or the It can be carried out by an affinity purification method using a membrane protein, filtration using a porous membrane such as a filter, or the like.
- a commercially available kit may be used for the isolation or extraction of the extracellular vesicles, and as a specific example, the qEv isolation kit (manufactured by Izon Sciences) can be used.
- the extracellular vesicles contain components derived from the regenerative cell population.
- the extracellular vesicle has, for example, a lipid bilayer membrane and a lumen, and the lumen is surrounded by the lipid bilayer membrane.
- the lipid bilayer membrane is, for example, derived from the membrane of the regenerative cell population, specifically the membrane of the cells of the regenerative cell population. Examples of the membrane include cell membranes; membranes of intracellular organelles such as mitochondria, endoplasmic reticulum, endosomes, lysosomes, and Golgi apparatus; and the like.
- the lumen has, for example, cytoplasm derived from the regenerative cell population, specifically cytoplasm derived from cells of the regenerative cell population.
- said extracellular vesicles comprise, for example, miRNA, DNA and/or proteins derived from the cytoplasm of cells of said regenerative cell population.
- the lipid bilayer membrane of the extracellular vesicles includes, for example, membrane components of the cells of the regenerative cell population.
- the extracellular vesicles can be defined using, for example, membrane components present in the regenerative cell population.
- the membrane components include membrane proteins.
- the membrane proteins include extracellular vesicle markers such as CD9, CD63, Alix (ALG-2-interacting protein X), Hsp-70 (Heat Shock Protein 70); cell surface markers of the cells; .
- the cell surface marker can be appropriately determined according to the cell type.
- the cell surface markers include, for example, CD34, CD133, KDR (Kinase insert domain receptor, CD309), CD105, and the like.
- the cell surface markers include, for example, CD206, CD163, CD169 and the like.
- the lipid bilayer membrane of the extracellular vesicle contains, for example, one or more membrane components.
- the membrane component can be measured by flow cytometry using, for example, an antibody against the molecule of interest.
- the lumen of the extracellular vesicles contains, for example, the cytoplasm of the cells of the regenerative cell population.
- the extracellular vesicles can be defined using, for example, cytoplasmic components present in the regenerative cell population. Examples of the cytoplasmic components include miRNA and the like.
- the miRNAs are, for example, miR-15b-5p, miR-29b-3p, miR-29c-3p, miR-92a-2-5p, miR-126-3p, miR-126-5p, miR-133a-3p, miR-133b, miR-146a-3p, miR-146b-5p, miR-150-5p, miR-181b-3p, miR-195-3p, miR-195-5p, miR-200b-5p, miR-302a- 5p, miR-142-3p, miR-10a-3p, miR-17-3p, miR-20b-5p, miR-21-5p, miR-24-2-5p, miR-29a-5p, miR-30b- 5p, miR-30c-5p, miR-30e-3p, miR-30e-5p, miR-32-5p, miR-92a-3p, miR-103a-2-5p, miR-144-5p, miR-148a- 3p, miR-199b-5p,
- miRNAs in particular miR-92a-2-5p, miR-133a-3p, miR-133b, miR-146a-3p, miR-200b-5p, miR-302a-5p and miR-142-3p is assumed to be a specific miRNA in extracellular vesicles of said regenerative cell population.
- the lumen of the extracellular vesicles contains miR-92a-2-5p, miR-133a-3p, miR-133b, miR-146a-3p, miR-200b-5p, miR-302a-5p, and /or preferably contains miR-142-3p.
- the lumen of the extracellular vesicle contains, for example, one or more cytoplasmic components.
- Said cytoplasmic components can be measured by flow cytometry, for example using antibodies against the molecule of interest.
- the cytoplasmic component is a nucleic acid molecule
- the cytoplasmic component can be measured using, for example, a sequencer or the like.
- the miRNAs are, for example, miR-15b-5p, miR-29b-3p, miR-92a-2-5p, miR-146a-3p, miR-146b-5p, miR -150-5p, miR-195-3p, miR-195-5p, miR-200b-5p, miR-302a-5p, and/or miR-142-3p.
- the miRNAs are, for example, miR-10a-3p, miR-17-3p, miR-20b-5p, miR-21-5p, miR-24-2-5p , miR-29a-5p, miR-30b-5p, miR-30c-5p, miR-30e-3p, miR-30e-5p, miR-32-5p, miR-92a-3p, miR-103a-2-5p , miR-144-5p, miR-148a-3p, miR-199b-5p, miR-200a-3p, miR-205-5p, miR-210-3p, miR-221-5p, miR-324-5p, miR -363-3p, miR-373-3p, miR-509-3p, miR-633, and/or let-7c-5p.
- miR-20b-5p, miR-30b-5p, miR-30c-5p, miR-30e-3p, miR-30e-5p, miR-32-5p, miR-92a-2-5p, miR- 92a-3p, miR-199b-5p, miR-200a-3p, miR-363-3p, and miR-509-3p are generally known to have anti-apoptotic activity.
- miRNAs In the miRNA, miR-17-3p, miR-20b-5p, miR-103a-2-5p, miR-150-5p, miR-181b-3p, miR-200a-3p, miR-205-5p, miR- 302a-5p, miR-324-5p, miR-363-3p, and miR-633 are generally known to have cell growth promoting activity. Among the miRNAs, miR-150-5p is generally known to have cell migration-promoting activity.
- miRNA-21-5p, miR-29a-5p, miR-29b-3p, miR-29c-3p, miR-133a-3p, miR-133b, miR-200a-3p, and miR-373-3p is generally known to have antifibrotic activity, particularly TGF- ⁇ expression-suppressing activity.
- miRNAs In the miRNA, miR-15b-5p, miR-29c-3p, miR-126-3p, miR-126-5p, miR-146a-3p, miR-146b-5p, miR-181b-3p, miR-195- 3p, miR-195-5p, miR-200b-5p, miR-210-3p, miR-221-5p, miR-633, and let-7c-5p can generally have pro-angiogenic activity.
- miRNAs miR-10a-3p, miR-21-5p, miR-24-2-5p, miR-142-3p, miR-144-5p, and miR-148a-3p are generally anti-inflammatory known to be active.
- the components contained in the lumen may be replaced with components other than the cytoplasm of the regenerative cell population.
- the lumen carries the desired cargo.
- the cargo include low-molecular-weight compounds, proteins such as antibodies, peptides, and nucleic acids.
- the average diameter (weighted average) of the extracellular vesicles is, for example, 1 to 500 nm, preferably 10 to 250 nm, more preferably 30 to 150 nm.
- the average diameter can be measured according to Example 1 described later.
- the average diameter of the extracellular vesicles can be adjusted, for example, by filtering the liquid containing the extracellular vesicles using a filter or the like having a desired pore size.
- the extracellular vesicles or composition of the present invention may further contain a pharmaceutically acceptable carrier.
- the carrier includes a suspending agent, a solubilizer, a stabilizer, a tonicity agent, a preservative, an antiadsorption agent, a surfactant, a diluent, a medium, and a pH adjuster for administering the extracellular vesicles.
- soothing agents, buffering agents, sulfur-containing reducing agents, antioxidants, etc. and can be appropriately added within a range that does not impair the effects of the present invention.
- Extracellular vesicles or compositions of the invention may be used, for example, in vitro or in vivo .
- Extracellular vesicles or compositions of the invention can be used, for example, as research reagents or as pharmaceuticals.
- the subject of administration of the extracellular vesicles or composition of the present invention is not particularly limited.
- the administration subject includes, for example, humans or non-human animals other than humans.
- non-human animals include mammals such as mice, rats, rabbits, dogs, cats, cows, horses, pigs, monkeys, dolphins, and sea lions; birds; fish;
- the subject of administration includes, for example, cells, tissues, organs, organs, etc., and the cells are, for example, cells collected from living organisms.
- tissue, organ, or organ includes, for example, a tissue (biological tissue) or organ collected from a living body.
- the cells include muscle cells, iPS cells (induced pluripotent stem cells), stem cells, and the like.
- the administration subject includes, for example, subjects diagnosed or suspected of having ischemic heart disease.
- the ischemic heart disease include myocardial infarction, peripheral artery disease, myocardial ischemia-reperfusion injury, severe lower extremity ischemia, and the like.
- the conditions for use (administration conditions) of the extracellular vesicles or composition of the present invention are not particularly limited, and for example, the dosage form, administration period, dosage, etc. can be appropriately set according to the type of administration subject.
- Methods for administering extracellular vesicles or compositions of the present invention include, for example, oral administration and parenteral administration such as intravenous administration. Intravenous administration is preferred, as it can be administered over a period of time.
- the dosage of the extracellular vesicles or compositions of the invention is an effective dosage, specifically for the treatment of ischemic heart disease when administered to a subject relative to the disease compared to a subject who has not been administered. It is the amount at which an effect (therapeutic effect) can be obtained.
- the dose can be appropriately determined according to, for example, the age, body weight, symptoms, etc. of the subject.
- the dose is, for example, 10 4 to 10 9 extracellular vesicles/kg body weight, 10 4 to 10 8 cells/kg body weight, 10 4 to 10 7 extracellular vesicles per administration. /kg body weight, preferably 10 4 to 10 8 cells/kg body weight, 10 4 to 10 7 cells/kg body weight.
- the number of administrations of the extracellular vesicles or composition of the present invention is one or more.
- the plurality of times is, for example, 2 times, 3 times, 4 times, 5 times or more.
- the frequency of administration may be appropriately determined while confirming the therapeutic effect of the subject.
- the administration interval can be appropriately determined while confirming the therapeutic effect of the subject, for example, once a day, once a week, once every two weeks, once a month, once every three months. , once every six months, etc.
- the extracellular vesicles or composition of the present invention suppresses the graft rejection reaction and is derived from the regenerative cell population, and thus has physiological activities such as angiogenesis-promoting activity. Therefore, the extracellular vesicles or composition of the present invention can be suitably used for treating ischemic heart disease or improving prognosis, for example, as described later.
- the invention provides compositions or methods of using same for use in treating ischemic heart disease.
- the present invention is a composition for use in treating ischemic heart disease, said composition being the extracellular vesicles or composition of the present invention.
- the present invention also provides a method for treating a patient with ischemic heart disease, comprising administering the extracellular vesicles or composition of the present invention to the patient with ischemic heart disease.
- the ischemic diseases include, for example, myocardial infarction, peripheral artery disease, myocardial ischemia-reperfusion injury, severe lower extremity ischemia, and the like.
- the present invention provides compositions for use in promoting proliferation of vascular endothelial cells or methods of using the same.
- the present invention is a composition for use in promoting proliferation of vascular endothelial cells, wherein the composition is the extracellular vesicle or composition of the present invention.
- the present invention also provides a method for promoting proliferation of vascular endothelial cells, comprising the step of promoting proliferation of the vascular endothelial cells by contacting the vascular endothelial cells with a composition, wherein the composition comprises: including extracellular vesicles or compositions of the invention.
- the present invention provides compositions for use in inducing angiogenesis or methods of using the same.
- the present invention is a composition for use in inducing angiogenesis, wherein the composition is the extracellular vesicle or composition of the present invention.
- the present invention is also a method of inducing angiogenesis using the extracellular vesicles or compositions of the present invention.
- the extracellular vesicles or composition is administered to a subject for which angiogenesis is to be induced.
- the subject to induce angiogenesis is, for example, a patient with ischemic heart disease.
- the induction of angiogenesis can also be referred to as the induction of angiogenesis in the heart of the patient or in sites where ischemia-reperfusion injury has occurred (eg, central or peripheral blood vessels).
- the present invention provides a composition for use in inhibiting fibrosis or a method using the same.
- the present invention is a composition for use in suppressing fibrosis, wherein the composition is the extracellular vesicle or composition of the present invention.
- the present invention also provides a method for suppressing fibrosis, which uses the extracellular vesicles or composition of the present invention.
- the extracellular vesicles or composition is administered to a subject whose fibrosis is to be suppressed.
- Patients with ischemic heart disease for example, can be mentioned as subjects for which fibrosis is to be suppressed.
- the induction of angiogenesis can also be referred to as suppression of fibrosis in the patient's heart or sites where ischemia-reperfusion injury has occurred (eg, central or peripheral blood vessels).
- the present invention is an extracellular vesicle or composition for use in treating ischemic heart disease.
- the present invention is also an extracellular vesicle or composition for use in promoting proliferation of vascular endothelial cells.
- the present invention is an extracellular vesicle or composition for use in promoting angiogenesis.
- the present invention is an extracellular vesicle or composition for use in suppressing fibrosis.
- Example 1 It was confirmed that the extracellular vesicles of the present invention have vascular endothelial cell proliferation activity, angiogenesis-promoting activity, fibrosis-suppressing activity, and reduced graft rejection.
- a regenerative cell population was prepared by deriving from human peripheral blood mononuclear cells. First, 20-100 ml of peripheral blood was collected from healthy volunteers aged 20-55 using a heparinized butterfly needle attached to a 50 ml syringe. Prior to the collection, informed consent was obtained from each healthy subject. In addition, the collection was performed under the approval of the Medical Research Committee of Tokai University School of Medicine, and the obtained peripheral blood samples were handled in accordance with the biological guidelines for human samples. In addition, the following animal experiments were conducted in accordance with the guidelines for handling experimental animals (National Research Council) and with the approval of the Animal Care and Use Committee of Tokai University School of Medicine.
- PBMNC peripheral blood mononuclear cells
- the CD34 positive rate was 0.23 ⁇ 0.03% and the CD133 positive rate was 0.20 ⁇ 0.07% in the isolated PBMNC.
- the number of CD34-positive cells per 100 ml of peripheral blood was (27.8 ⁇ 4.5) ⁇ 10 4 and the number of CD133-positive cells was (23.2 ⁇ 6.9) ⁇ 10 4 .
- the serum-free medium (hereinafter also referred to as "QQ medium” or “QQcm") used for culturing (inducing) the regenerative cell population is stemline (trademark) II Hematopoietic Stem Cell Expansion Medium (Sigma-Aldrich, Cat No. S0192).
- QQ medium used for culturing (inducing) the regenerative cell population
- stemline trademark
- QQcm Hematopoietic Stem Cell Expansion Medium
- rhSCF (Concentration of each factor in QQ medium): 100 ng/ml rhFlt3L (manufactured by Peprotech, Inc., Cat. No. #300-19): 100 ng/ml rhTPO (manufactured by Peprotech, Inc., Cat. No. #300-18): 20 ng/ml rhVEGF (manufactured by Peprotech, Inc., Cat. No. #100-02): 50 ng/ml rhIL-6 (manufactured by Peprotech, Inc., Cat. No. #200-06): 20 ng/ml Penicillin/streptomycin (manufactured by Gibco, Cat. No. 15140122: 100 U/100 ⁇ g/ml) r: recombinant h: human-derived
- the composition of the extracellular vesicle-producing medium was X-vivo 15 medium (manufactured by Lonza, Cat. No. BE02-054Q) supplemented with 5 (v/v)% exosome-depleted fetal bovine serum.
- the resulting cell suspension was plated in 10 cm dishes at 2.5 ⁇ 10 5 cells/ml/dish (250k) or 5 ⁇ 10 5 cells/ml/dish (500k) for 48 hours after seeding. cultured.
- the culture supernatant (conditioned medium) was recovered, and the cells were removed by centrifuging the culture supernatant at 300 ⁇ g and 4° C. for 10 minutes.
- the obtained supernatant fraction was centrifuged at 2000 ⁇ g and 12° C. for 20 minutes, and the supernatant fraction was collected to remove apoptotic bodies and microvesicles.
- the supernatant fraction was filtered through a 0.2 ⁇ m filter (manufactured by Millipore Merck, Cat. No. SLGS033SS) to remove extracellular vesicles with a particle size exceeding 200 nm. Then, the obtained filtrate was centrifuged at 174000 ⁇ g and 4° C.
- CM-Dil dye (C7000, manufactured by Thermo Fisher) was added to the filtrate after filtration through the 0.2 ⁇ m filter so that the concentration became 2 ⁇ mol/l. , labeled. After centrifuging the obtained reaction solution at 174000 ⁇ g and 4° C. for 110 minutes, the extracellular vesicles were washed with PBS and centrifuged under the same conditions. A similar wash and hyperopia was performed again. Then, the collected precipitate was suspended in the medium or buffer solution (up to 3 ⁇ 50 ⁇ l) used in each experiment described below.
- extracellular vesicles were measured after calibrating the flow cytometer (DxFlex FACS machine, manufactured by Beckman Coulter) using latex beads of different sizes (100 nm or 200 nm). Furthermore, the particle size of each extracellular vesicle was calculated by comparing the intensity of the obtained side scattered light (SSC) with the intensity of the latex beads and the intensity of each extracellular vesicle. Then, based on the obtained particle diameters, the average diameter (weighted average) was calculated.
- SSC side scattered light
- the particle size of each extracellular vesicle was calculated in the same manner except that a nanoparticle tracking analysis (NTA) device (ZetaView (registered trademark), manufactured by DKSH) was used, The average diameter (weighted average) was calculated. Then, it was confirmed that the average diameter obtained by the flow cytometer and the average diameter obtained by the NTA apparatus were almost the same value.
- NTA nanoparticle tracking analysis
- the expression of the marker is determined by anti-CD9 antibody (PE-labeled, Biolegend, Cat. No. #312106) or anti-CD63 antibody (PE-labeled, Biolegend, Cat. No. #353004). After staining with anti-Alix antibody (Alexa 594-labeled, Biolegend, Cat. No. #634504) and anti-Hsp-70 antibody (Alexa 488-labeled, Biolegend, Cat. No. #648003), It was measured using the flow cytometer described above. Controls were performed in the same manner except that control antibodies were used instead of various antibodies.
- the amount of extracellular vesicles produced per cell (the number of extracellular vesicles) per 2.5 ⁇ 10 5 cells was calculated based on the sample volume counted and measured by the flow cytometer. .
- the structure of the lipid membrane and lumen was observed using a scanning electron microscope (JEM-1400, manufactured by JEOL Ltd.).
- the reference example was performed in the same manner, except that human-derived mesenchymal stem cells (MSC, manufactured by Lonza, Cat. No. BE02-054Q) were used instead of the RAC. These results are shown in FIGS. 1-3. Statistical processing in the graph was performed using the Mann-Whitney test.
- Figure 1 is a graph showing the particle size, production amount per cell, and average size of extracellular vesicles.
- FIG. 1 shows the result of particle diameter
- (B) shows the result of production amount
- (C) shows the result of average diameter.
- the horizontal axis indicates the particle diameter (logarithm) and the vertical axis indicates the relative number.
- the horizontal axis indicates the type of sample
- the vertical axis indicates the number of extracellular vesicles produced.
- the horizontal axis indicates the type of sample
- the vertical axis indicates the average diameter. As shown in FIGS.
- RAC-derived extracellular vesicles are slightly larger than MSC-derived extracellular vesicles (MSCev), and the average diameter of RACev is 145 nm. while MSCev was 130 nm.
- RAC produced significantly more extracellular vesicles per cell than MSC.
- FIG. 2 is an electron microscope image showing the structure of RAC-derived extracellular vesicles.
- RACev has a lipid bilayer membrane structure and a lumen, the lumen is surrounded by the lipid bilayer membrane, and has a structure similar to that of extracellular vesicles such as MSCev. I was able to confirm that I have.
- FIG. 3 is a histogram showing the expression of markers.
- (A) shows the results of RACev
- (B) shows the results of MSCev.
- the horizontal axis indicates the intensity of SSC or the fluorescence intensity of each marker
- the vertical axis indicates the count.
- FIGS. 3A and 3B the horizontal axis indicates the intensity of SSC or the fluorescence intensity of each marker, and the vertical axis indicates the count.
- the left diagram of FIG. 3(A) it was found that the particle size of extracellular vesicles can be measured with a flow cytometer by using latex beads with a known particle size.
- the expression of CD63 and CD9 was confirmed in RACev.
- RACev had a higher expression level of CD63 than MSCev. Although not shown in FIG. 3(A), the expression of Alix and HSP70 was also confirmed in RACev. These results show that RACev expresses exosome markers and can be distinguished from MSCev by CD9 and Alix expression.
- vascular endothelial Cell Growth-Promoting Activity The vascular endothelial cell growth-promoting activity of RACev was examined using human fetal vascular endothelial cells (HUVEC, manufactured by Lonza, Cat. No. C2517A, Batch #. 18TL061650). . Specifically, after collecting HUVECs that have been subcultured 3 to 4 times, Cytopainter dye (manufactured by Abcam, Cat. No. #ab176735) is added and incubated at 37° C. for 10 to 30 minutes. HUVEC cells were labeled. After the labeling, centrifugation and washing were repeated twice.
- HUVEC human fetal vascular endothelial cells
- the obtained HUVEC cells were seeded in a 3.5 cm dish at 5 ⁇ 10 4 cells/2 ml/dish.
- EGM-2 manufactured by Lonza
- EBM-2 manufactured by Lonza
- Extracellular vesicles isolated from 250k or 500k RAC or MSCs were then added to each dish. Then, it was cultured for 2 days under the above culture conditions. After the culture, each dish was observed using a phase-contrast microscope (6-well dish, manufactured by Falcon). In the phase-contrast images obtained, the number of cells per field of view (HPF) was counted, and the ratio of the area occupied by HUVEC cells to the total area was calculated as the growth area.
- HPF phase-contrast microscope
- HUVEC cells were recovered from the dish, and division of the HUVEC cells was measured using the above label as an index using a flow cytometer (FACS Verse, manufactured by BD Biosciences). Moreover, control was implemented similarly except that RACev and MSCev were not added.
- miRNA analysis was performed on RACev and MSCev added during HUVEC cell culture.
- miRNA was purified using miRNA purification kits (miRNeasy mini kit and RNeasy MinElute Cleanup Kit, manufactured by QIAGEN).
- a library for sequencing was prepared using the obtained miRNA and a library construction kit (QIAseq (trademark) miRNA Library Kit, manufactured by Qiagen, Cat. No. #331505).
- QIAseq (trademark) miRNA Library Kit manufactured by Qiagen, Cat. No. #331505
- a quality check of the library was performed using Agilent Bioanalyze and a DNA chip (High Sensitivity DNA chip, manufactured by Agilent Technologies).
- the sequence of the library was decoded as a 76 bp (bp) single-ended read using a next-generation sequencer (NextSeq 500, manufactured by Illumina). Then, from the obtained sequence data, the expression level of each miRNA (miR-181b-3p, miR-150-5p, miR-302a-5p, miR-92a-2-5p) was calculated. The relative expression level was calculated based on the expression level of each miRNA in HUVEC cells to which extracellular vesicles were not added.
- NextSeq 500 next-generation sequencer
- Figure 4 is a graph showing the proliferation of HUVEC cells.
- the horizontal axis indicates the type of sample, and the vertical axis indicates the number of cells per field of view (HPF).
- RACev and MSCev promoted proliferation of vascular endothelial cells compared to controls.
- RACev significantly promoted the proliferation of vascular endothelial cells compared to MSCev (MSCev-250K vs. RACev-250K: P>0.001, MSCev-500K vs. RACev-500K : P>0.0001).
- FIG. 5 is a photograph and graph showing the growth area of HUVEC cells.
- (A) shows a phase contrast image
- (B) shows a graph of growth regions.
- the horizontal axis indicates the type of sample
- the vertical axis indicates the growth region.
- RACev and MSCev increased the growth area of vascular endothelial cells compared to the control.
- RACev significantly increased the growth area of vascular endothelial cells compared to MSCev (MSCev-500K vs. RACev-500K: P>0.0007). .
- FIG. 6 is a graph showing the expression level of miRNA.
- the horizontal axis indicates the type of miRNA, and the vertical axis indicates the relative expression level.
- RACev significantly increased miRNAs with anti-apoptotic activity (miR-92a-2-5p) and miRNAs with mitogenic activity (miR-181b-3p, miR -150-5p, miR-302a-5p) and miRNA with cell migration promoting activity (miR-150-5p) were highly expressed. From these results, it was found that RACev exhibits proliferation-promoting activity for vascular endothelial cells by transporting miRNAs with anti-apoptotic activity and miRNAs with mitogenic activity.
- ischemic heart disease prognosis is improved when angiogenesis occurs due to proliferation of vascular endothelial cells. Therefore, we confirmed that RACev contributes to improvement of ischemic heart disease using a rat model of myocardial infarction. Specifically, Lewis rats (male, 6 to 10 weeks old, weighing 150 to 250 g, purchased from Charles River Japan) were intubated, and 3 to 4% sevoflurane (manufactured by Maruishi Pharmaceutical Co., Ltd.) was added at 15 ml/ml. Anesthesia was achieved by inhalation at kg for 65-70 minutes.
- ischemia-reperfusion injury was induced by reperfusion after 30 minutes of ischemia for the left anterior descending artery (LAD). After the induction, the ribcage was closed immediately.
- extracellular vesicles (RACev or MSCev) isolated from 500 k RACs or MSCs were diluted with PBS, and the resulting dilutions were incubated for a predetermined time (30 minutes after induction of ischemia-reperfusion injury). , 1 and 2 days later) via the tail vein.
- the degree of ischemic heart disease was assessed by echocardiography. Specifically, using an echocardiography device (manufactured by Aloka) equipped with a 3.5 MHz probe, left ventricular end diastolic diameter (LVDD), left ventricular end systolic diameter (LVDS), and mitral regurgitation (MR) severity, E-wave and A-wave heights, and left atrial and ascending aorta sizes were measured. The measurements were performed initially before the induction of the ischemia-reperfusion injury (baseline) and then weekly for up to 4 weeks after the induction of the injury. The severity of mitral valve regurgitation was evaluated according to the following criteria.
- %FS left ventricular diameter shortening fraction
- Score 3 (severe): reflux reaching the left atrium wall
- Score 2 (moderate): reflux reaching 2/3 of the left atrium
- Score 1 (mild/slight): reflux reaching 1/3 of the left atrium
- FIG. 7 is a photograph showing an echogram and a graph showing the ejection fraction and the left ventricle inner diameter shortening fraction.
- (A) is the control result
- (B) is the MSCev result
- (C) is the RACev result
- (D) is the ejection fraction result
- (E) is the left ventricle diameter.
- Shortening rate results are shown.
- long arrows indicate examples of LVDD
- short arrows indicate examples of LVDS.
- the horizontal axis indicates the time before and after induction of the ischemia-reperfusion injury
- the vertical axis indicates the ejection fraction.
- the horizontal axis indicates the time before and after the induction of ischemia-reperfusion injury, and the vertical axis indicates the left ventricular inner diameter shortening ratio.
- RACev improved ejection fraction and significantly improved left ventricular fractional shortening compared to controls and MSCev.
- FIG. 8 is a graph showing the severity of mitral valve regurgitation and the left ventricular end-systolic volume.
- (A) shows the results of severity of mitral valve regurgitation
- (B) shows the results of left ventricular end-systolic volume.
- the horizontal axis indicates the time before and after induction of the ischemia-reperfusion injury
- the vertical axis indicates the severity of mitral regurgitation.
- the horizontal axis indicates the time before and after induction of the ischemia-reperfusion injury
- the vertical axis indicates the left ventricular end-systolic volume.
- RACev improved the severity of mitral regurgitation compared to controls and MSCev and returned to normal levels 4 weeks after the ischemia-reperfusion injury. rice field. Also, as shown in FIG. 8(B), RACev improved left ventricular end-systolic volume compared to controls and MSCev. It is presumed that RACev improved the severity of mitral regurgitation.
- Fibrosis occurs in ischemic heart disease caused by ischemia-reperfusion injury. Therefore, it was confirmed whether fibrosis is suppressed by administration of RACev.
- hearts were harvested from the rats. After perfusion with PBS containing 1000 U/ml heparin, the heart was fixed overnight (about 8 hours) with 4% paraformaldehyde (manufactured by Fujifilm, Cat. No. #163-20145). After the fixation, the heart was embedded in paraffin and 3-4 ⁇ m thick paraffin-embedded sections were prepared.
- FIG. 9 is a graph and photographs showing the degree of fibrosis.
- (A) shows the size of interstitial fibrosis
- (B) shows representative examples of each sample.
- dark gray areas indicate fibrosis areas.
- FIG. 9A the horizontal axis indicates the type of sample, and the vertical axis indicates the size of interstitial fibrosis.
- RACev and MSCev significantly suppressed the degree of fibrosis compared to control.
- FIG. 10 is a graph showing the expression level of miRNA.
- the horizontal axis indicates the type of miRNA, and the vertical axis indicates the relative expression level.
- RACev had significantly higher expression levels of miRNAs having fibrosis-suppressing activity than MSCev. From these results, it was found that RACev exhibits anti-fibrosis activity by transporting miRNAs having anti-fibrosis activity.
- the blood vessel density was calculated from the obtained microscopic images. Controls were performed similarly except that RACev and MSCev were not administered. In addition, for RACev and MSCev added during the culture of HUVEC cells, each miRNA (miR-126-3p, mmiR-195-3p, miR-29c-3p, miR- 126-5p, miR-15b-5p, miR-195-5p, miR-200b-5p, miR-146a-3p, miR-146-5p) were calculated. These results are shown in FIGS. 11-12. For statistical processing in the graph, Dunn's multiple comparison test was performed.
- FIG. 11 is a photograph and graph showing blood vessels in infarcted myocardial tissue.
- (A) shows blood vessels in infarcted myocardial tissue and
- (B) shows the density of blood vessels.
- the horizontal axis indicates the type of sample, and the vertical axis indicates the density of blood vessels in the infarcted myocardial tissue.
- RACev significantly increased vascular density compared to controls and MSCev.
- FIG. 12 is a graph showing the expression level of miRNA.
- the horizontal axis indicates the type of miRNA, and the vertical axis indicates the relative expression level.
- RACev had significantly higher expression levels of miRNAs having angiogenesis-promoting activity than MSCev. These results show that RACev exhibits pro-angiogenic activity by transporting miRNAs having pro-angiogenic activity.
- Example 1 ischemia-reperfusion injury was induced, and the thorax was quickly closed after the induction.
- Extracellular vesicles (RACev or MSCev) isolated from 500 k RACs or MSCs were then diluted in PBS and the resulting dilutions were administered via the tail vein immediately after induction of the ischemia-reperfusion injury. .
- Hearts were harvested from the rats 3.5 hours after the administration. Then, the accumulation of RACev in the infarcted myocardial tissue of the heart was measured using a fluorescence imaging system (IVIS Lumina III, Perkin Elmer). The excitation wavelength was 520 nm and the emission wavelength was 570 nm.
- a luminance value per unit area was calculated from the measured values obtained.
- 6 ⁇ m-thick frozen sections were prepared from the collected hearts, and the obtained frozen sections were observed with a confocal microscope (LSM880, Carl Zeiss) after nuclear staining. Controls were performed similarly except that RACev or MSCev was not administered. These results are shown in FIGS. 13-14. Statistical processing in the graph was performed using the Mann-Whitney test.
- FIG. 13 is a photograph showing a fluorescent image of infarcted myocardial tissue.
- the upper row shows the control results
- the middle row shows the MSCev results
- the lower row shows the RACev results.
- the left column is the result of detection of labeled extracellular vesicles (RACev or MSCev)
- the middle column is the result of detection of labeled extracellular vesicles (RACev or MSCev) and nuclei
- the right column is These merge results are shown.
- RACev and MSCev were observed to accumulate in infarcted myocardial tissue.
- RACev was accumulated more than MSCev, and uptake into the nuclei of cardiomyocytes was observed as indicated by arrows in the figure.
- FIG. 14 is a photograph and graph showing the luminescence intensity of infarcted myocardial tissue.
- (A) is a photograph showing the luminescence intensity of the infarcted myocardial tissue
- (B) is a graph showing the luminescence intensity per unit area.
- RACev was observed to accumulate more extracellular vesicles in the infarcted myocardial tissue than MSCev. From the above, it was confirmed that RACev is excellent in accumulating in inflamed tissue.
- spleens were harvested and weighed.
- peripheral blood and spleens were collected 4 weeks after the induction.
- the percentages of CD3-positive cells, CD4-positive cells, CD8-positive cells, regulatory T cells and CD11b/c-positive cells in the peripheral blood were measured using a flow cytometer.
- the ratio of CD3-positive cells, CD4-positive cells, CD8-positive cells, TNK, iNK and antigen-presenting cells, which are markers of graft rejection in the spleen, to regulatory T cells was measured using a flow cytometer. was measured using Controls were performed similarly except that RACev and MSCev were not administered.
- FIG. 15 is a graph showing rat body weight and spleen weight.
- (A) shows the results of rat body weight
- (B) shows the results of spleen weight.
- the horizontal axis indicates the time of measurement based on ischemia-reperfusion induction
- the vertical axis indicates the body weight of the rat.
- the horizontal axis indicates the time of measurement based on ischemia-reperfusion induction (IR-injury)
- the vertical axis indicates the weight of the spleen.
- FIGS. 15(A) and (B) there was no difference between RACev, MSCev and controls, and no graft rejection was observed.
- FIG. 16 is a graph showing the ratio of CD3-positive cells, CD4-positive cells, CD8-positive cells, regulatory T cells and CD11b/c-positive cells.
- the horizontal axis indicates the type of sample, and the vertical axis indicates the proportion of each cell. As shown in Figure 16, there was no difference between RACev, MSCev and controls and no graft rejection was observed.
- FIG. 17 is a graph showing the ratio of CD3-positive cells, CD4-positive cells, CD8-positive cells, TNK, iNK, regulatory T cells and CD11b/c-positive cells.
- the horizontal axis indicates the type of sample, and the vertical axis indicates the percentage of each cell. As shown in Figure 17, there was no difference between RACev, MSCev and controls and no graft rejection was observed.
- FIG. 18 is a graph showing the expression level of miRNA.
- the horizontal axis indicates the sample type, and the vertical axis indicates the relative expression level.
- RACev had a significantly higher expression level of miRNA (miR-142-3p) having immunosuppressive activity (anti-inflammatory) than MSCev.
- miR-142-3p is known to be contained in exosomes released by regulatory T cells (Treg). These results suggest that RACev suppresses graft rejection by transporting miRNAs with immunosuppressive activity.
- the extracellular vesicles of the regenerative cell population i.e., the extracellular vesicles of the present invention, have vascular endothelial cell proliferation activity, angiogenesis-promoting activity, and fibrosis-suppressing activity. , and graft rejection were found to be reduced.
- Example 2 It was confirmed that a regenerative cell population can be induced by culturing peripheral blood mononuclear cells or cord blood mononuclear cells with various factors.
- Peripheral blood mononuclear cells were prepared in the same manner as in Example 1(1).
- Cord blood mononuclear cells were also prepared in the same manner, except that cord blood was used instead of the peripheral blood.
- peripheral blood mononuclear cells and the umbilical cord blood mononuclear cells were regenerated in the same manner as in Example 1 (1) except that the serum-free medium and each factor were used under conditions 1 to 6 below.
- Sexual cell populations (RAC) were prepared.
- the combination of the peripheral blood mononuclear cells and condition 6 below corresponds to the culture conditions of Example 1(1).
- the number of cells in the resulting regenerative cell population was counted.
- the relative ratio of the number of cells was calculated based on the number of seeded cells. Controls were the peripheral blood mononuclear cells and cord blood mononuclear cells.
- SS3G Serum-free medium StemSpan SFEM (manufactured by Stemcell Technologies) Each factor: rhSCF: 100ng/ml rhFlt3L: 100ng/ml rhTPO: 20ng/ml ⁇ Condition 2: SS5G Serum-free media: StemSpan SFEM Each factor: rhSCF: 100ng/ml rhFlt3L: 100ng/ml rhTPO: 20ng/ml rhVEGF: 50ng/ml rhIL-6: 20ng/ml ⁇ Condition 3: SC3G Serum-free medium: StemCell Each factor: rhSCF: 100ng/ml rhFlt3L: 100ng/ml rhTPO: 20ng/ml ⁇ Condition 4: SC5G Serum-free medium: StemCell Each factor: rhSCF: 100ng/ml rhFlt3L: 100ng/ml
- FIG. 19 is a graph showing the number of cells.
- (A) shows the results using peripheral blood mononuclear cells
- (B) shows the results using cord blood mononuclear cells.
- the horizontal axis indicates the conditions
- the vertical axis indicates the relative ratio of cell numbers.
- FIG. 19(A) when the peripheral blood mononuclear cells were used, the number of cells decreased under any conditions.
- the number of cells increased by using 5 factors compared to the case of using 3 factors.
- the cord blood mononuclear cells when the cord blood mononuclear cells were used, the number of cells decreased under any conditions.
- StemSpan SFEM was used as the serum-free medium, the number of cells increased compared to when other media were used.
- EPC-CFA EPC colony formation assay
- FIG. 20 is a graph showing the results of the EPC-CFA assay.
- (A) shows the results using peripheral blood mononuclear cells
- (B) shows the results using cord blood mononuclear cells.
- the horizontal axis indicates the conditions
- the vertical axis indicates the number of colonies of each EPC cell per 20,000 seeded cells.
- FIG. 20(A) almost no SEPC-CFU and DEPC-CFU were formed in the peripheral blood mononuclear cells.
- culturing under conditions 1 to 6 improved the ability of the peripheral blood mononuclear cell-derived cells to form SEPC-CFU and DEPC-CFU.
- the ability to form SEPC-CFU and DEPC-CFU is improved in the conditions 1 to 5 as in the condition 6, the peripheral blood mononuclear cells are induced by the conditions 1 to 5. It was also suggested that the cell group obtained from this method can be used as a regenerative cell group.
- SEPC-CFU and DEPC-CFU were formed to the same extent in the cord blood mononuclear cells.
- culturing under conditions 1 to 6 improved the ability of the peripheral blood mononuclear cell-derived cells to form SEPC-CFU and DEPC-CFU.
- the ability to form DEPC-CFU was improved. It was suggested that the cell populations induced by 1 to 6 could also be used as regenerative cell populations.
- the umbilical cord-derived extracellular vesicles of the present invention have miRNA having angiogenesis-promoting activity, miRNA having anti-apoptotic activity, miRNA having anti-fibrosis activity, miRNA having anti-fibrosis activity, and cell proliferation-promoting activity. Containing miRNA was confirmed.
- An umbilical cord-derived regenerative cell population was prepared by deriving from human cord blood-derived mononuclear cells or human cord blood-derived CD34-positive progenitor cells.
- human cord blood-derived mononuclear cells hereinafter, “CBMCs”, manufactured by Takara Bio Inc.
- CD34 cells human cord blood-derived CD34-positive vascular endothelial progenitor cells
- CBMCs human cord blood-derived mononuclear cells
- CD34 cells human cord blood-derived CD34-positive vascular endothelial progenitor cells
- the CBMCs were seeded in a 10-cm dish (manufactured by Sumitomo Bakelite Co., Ltd.) at 10 ⁇ 10 7 cells/10 ml/dish, and cultured for 7 days under conditions of 37° C., 5% CO 2 , and a humid environment. After seeding the CD34 cells in a 10 cm dish (manufactured by Sumitomo Bakelite Co., Ltd.) at 10 ⁇ 10 5 cells/10 ml/dish, the cells were kept at 37° C., 5% CO 2 in a humid environment for 7 days. cultured. This prepared a regenerative cell population (RAC).
- RAC regenerative cell population
- the CBMCs or CD34 cells were collected and then suspended in an extracellular vesicle production medium to prepare a cell suspension.
- the composition of the extracellular vesicle-producing medium was X-vivo 15 (manufactured by Lonza, Cat. No. BE02-054Q) to which 5 (v/v)% exosome-depleted fetal bovine serum was added. After the preparation, the cells were cultured for 48 hours.
- the culture supernatant (conditioned medium) was collected, and the cells were removed by centrifuging the culture supernatant at 300 xg and 4°C for 10 minutes.
- the obtained supernatant fraction was centrifuged at 2000 ⁇ g and 12° C. for 20 minutes, and the supernatant fraction was collected to remove apoptotic bodies and microvesicles.
- the supernatant fraction was filtered through a 0.2 ⁇ m filter (manufactured by Millipore Merck, Cat. No. SLGS033SS) to remove extracellular vesicles with a particle size exceeding 200 nm.
- the obtained filtrate was centrifuged at 174000 ⁇ g and 4° C. for 110 minutes to precipitate and collect extracellular vesicles (exosomes).
- each miRNA (miR-17-3p, miR-20b-5p, miR-92a-3p, miR-103a-2-5p, miR-126b-3p, miR-144-5p, miR-144-5p, miR- 148a-3p, miR-181b-3p, miR-200a-3p, miR-205-5p, miR-373-3p, miR-509-3p, miR-633) were calculated. These results are shown in FIG. As statistical processing in the graph, Tukey's multiple comparison test was performed after the Two-way ANOVA test.
- FIG. 21 is a graph showing the expression level of miRNA.
- (A) shows the expression level of miRNA with pro-angiogenic activity
- (B) shows the expression level of miRNA with anti-apoptotic activity
- (C) shows the miRNA with anti-fibrotic activity
- (D) shows the expression level of miRNA having anti-inflammatory activity
- (E) shows the expression level of miRNA having cell proliferation promoting activity.
- the horizontal axis indicates the type of RNA
- the vertical axis indicates the relative expression level. As shown in FIG.
- CB-MNCev has significantly more miRNAs with pro-angiogenic activity (miR-633, miR-126-3p) and miRNAs with anti-apoptotic activity (miR-92a -3p, miR-509-3p, miR-20b-5p, miR-200a-3p), miRNAs with antifibrotic activity (miR-373-3p, miR-200a-3p), miRNAs with anti-inflammatory activity ( miR-144-5p, miR-148a-3p), and miRNAs with cell proliferation promoting activity (miR-103a-2-5p, miR-633, miR-181b-3p, miR-20b-5p, miR-200a- 3p, miR-17-3p, miR-205-5p) were highly expressed.
- CB-MNCev is capable of suppressing miRNAs with pro-angiogenic activity, miRNAs with anti-apoptotic activity, miRNAs with anti-fibrotic activity, miRNAs with anti-fibrotic activity, and miRNAs with cell proliferation-promoting activity. found to contain
- each miRNA (miR-10a-3p, miR-17-3p, miR-20b-5p, miR-21-5p, miR-24-2-5p, miR-29a-5p, miR- 29c-3p, miR-30b-5p, miR-30c-5p, miR-30e-3p, miR-30e-5p, miR-32-5p, miR-126-3p, miR-126-5p, miR-133a- 3p, miR-133b, miR-199b-5p, miR-210-3p, miR-221-5p, miR-324-5p, miR-363-3p, let-7c-5p). did. These results are shown in FIG. As statistical processing in the graph, Tukey's multiple comparison test was performed after the Two-way ANOVA test.
- FIG. 22 is a graph showing the expression level of miRNA.
- (A) shows the expression level of miRNA with pro-angiogenic activity
- (B) shows the expression level of miRNA with anti-apoptotic activity
- (C) shows the miRNA with anti-fibrotic activity
- (D) shows the expression level of miRNA having anti-inflammatory activity
- (E) shows the expression level of miRNA having cell growth promoting activity.
- the horizontal axis indicates the type of miRNA, and the vertical axis indicates the relative expression level. As shown in FIG.
- CB-CD34ev has significantly more angiogenesis-promoting miRNAs (miR-126-3p, miR-210-3p, let-7c-5p, miR-126 -5p, miR-221-5p), miRNAs with anti-apoptotic activity (miR-199b-5p, miR-30e-5p, miR-30e-3p, miR-30c-5p, miR-30b-5p, miR-32 -5p, miR-20b-5p, miR-363-3p), miRNAs with antifibrotic activity (miR-29c-3p, miR-29a-5p, miR-21-5p, miR-133b, miR-133a- 3p), miRNAs with anti-inflammatory activity (miR-21-5p, miR-24-2-5p, miR-10a-3p), and miRNAs with cell proliferation-promoting activity (miR-20b-5p, miR-363- 3p, miR-324-5p, miR-17-3p) were highly expressed.
- CB-CD34ev is capable of suppressing miRNAs with pro-angiogenic activity, miRNAs with anti-apoptotic activity, miRNAs with anti-fibrosis activity, miRNAs with anti-fibrosis activity, and miRNAs with cell proliferation-promoting activity. found to contain
- cord blood-derived mononuclear cells or CD34-positive progenitor cells have angiogenesis-promoting activity, inflammation-suppressing activity, and apoptosis-suppressing activity. It was suggested to have vascular endothelial cell proliferation activity and to have anti-fibrosis activity.
- composition> (Appendix 1) A composition comprising extracellular vesicles of a regenerative cell population or culture thereof derived from mononuclear cells from a biological sample.
- the extracellular vesicles are miR-15b-5p, miR-29b-3p, miR-29c-3p, miR-92a-2-5p, miR-126-3p, miR-126-5p, miR-133a-3p , miR-133b, miR-146a-3p, miR-146b-5p, miR-150-5p, miR-181b-3p, miR-195-3p, miR-195-5p, miR-200b-5p, miR-302a -5p, and/or miR-142-3p.
- the extracellular vesicles are miR-10a-3p, miR-17-3p, miR-20b-5p, miR-21-5p, miR-24-2-5p, miR-29a-5p, miR-30b -5p, miR-30c-5p, miR-30e-3p, miR-30e-5p, miR-32-5p, miR-92a-3p, miR-103a-2-5p, miR-144-5p, miR-148a -3p, miR-199b-5p, miR-200a-3p, miR-205-5p, miR-210-3p, miR-221-5p, miR-324-5p, miR-363-3p, miR-373-3p , miR-509-3p, miR-633, and/or let-7c-5p.
- (Appendix 4) The composition of any one of Appendices 1 to 3, wherein said extracellular vesicles are CD9 and/or CD63 positive.
- (Appendix 5) The composition according to any one of appendices 1 to 4, wherein the extracellular vesicles have an average diameter of 10 to 500 nm.
- (Appendix 6) 6.
- (Appendix 7) 7.
- (Appendix 8) The composition according to any one of Appendices 1 to 7, which has fibrosis-suppressing activity.
- (Appendix 9) 9.
- composition according to any one of Appendices 1 to 8, wherein graft rejection is inhibited. (Appendix 10) 10.
- the regenerative cell population is induced by culturing the mononuclear cells in the presence of stem cell factor, interleukin 6, FMS-like tyrosine kinase 3 ligand, thrombopoietin, and/or vascular endothelial cell growth factor. 11.
- the composition according to any one of 1-10. (Appendix 12) 12.
- Appendix 13 13.
- Appendix 14 14.
- the composition of paragraph 13, wherein the vascular endothelial progenitor cells are differentiated EPC colony forming cells.
- the composition of paragraphs 13 or 14, wherein the anti-inflammatory macrophages are M2 macrophages.
- Appendix 16 16.
- composition for use in treating ischemic heart disease comprising: 18.
- Appendix 19 19. The composition of paragraph 18, wherein said ischemic heart disease is myocardial infarction.
- composition promoting proliferation of vascular endothelial cells (Appendix 20) A composition for use in promoting proliferation of vascular endothelial cells, 18. A composition, wherein the composition is a composition according to any one of Appendices 1 to 17.
- ⁇ Angiogenesis-inducing composition> (Appendix 21) A composition for use in inducing angiogenesis, comprising: 18. A composition, wherein the composition is a composition according to any one of Appendices 1 to 17.
- ⁇ Fibrosis suppressing composition> (Appendix 22) A composition for use in inhibiting fibrosis, comprising: 18. A composition, wherein the composition is a composition according to any one of Appendices 1 to 17.
- a method of treating a patient with ischemic heart disease comprising: 18.
- a method of treatment comprising administering a composition according to any one of appendices 1 to 17 to said patient with ischemic heart disease.
- Appendix 24 24.
- ⁇ Method for Promoting Proliferation of Vascular Endothelial Cells> (Appendix 25) A method for promoting proliferation of vascular endothelial cells, comprising: A step of promoting proliferation of the vascular endothelial cells by contacting the vascular endothelial cells with a composition, 18. The method, wherein the composition is a composition according to any of Appendixes 1-17.
- ⁇ Method of inducing angiogenesis> (Appendix 26) A method for inducing angiogenesis, comprising: 18. A method using a composition according to any one of appendices 1-17. (Appendix 27) 27. The method of paragraph 26, wherein said composition is administered to a subject to induce angiogenesis.
- Subjects for inducing angiogenesis are patients with ischemic heart disease, 29.
- ⁇ Method for inhibiting fibrosis> (Appendix 29) A method for inhibiting fibrosis, comprising: 18. A method using a composition according to any one of appendices 1-17. (Appendix 30) 30. The method of appendix 29, wherein the composition is administered to a subject whose fibrosis is to be suppressed.
- the target for suppressing fibrosis is a patient with ischemic heart disease, 31.
- appendix 29 or 30, wherein the inhibition of fibrosis is inhibition of fibrosis in the heart of the patient with ischemic heart disease.
- Appendix 32 A composition for use in treating ischemic heart disease, 18. The composition according to any one of Appendices 1 to 17.
- Appendix 33 A composition for use in promoting proliferation of vascular endothelial cells, 18. The composition according to any one of Appendices 1 to 17.
- Appendix 34 A composition for use in inducing angiogenesis, 18. The composition according to any one of Appendices 1 to 17.
- Appendix 35 A composition for use in inhibiting fibrosis, 18. The composition according to any one of Appendices 1 to 17.
- the extracellular vesicles or composition of the present invention suppresses the graft rejection reaction and is derived from the regenerative cell population. It has physiological activities such as Therefore, the present invention can be suitably used, for example, for treatment of ischemic heart disease or improvement of prognosis. Therefore, the present invention is extremely useful in, for example, the medical field.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Developmental Biology & Embryology (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Zoology (AREA)
- Virology (AREA)
- Biotechnology (AREA)
- Urology & Nephrology (AREA)
- Reproductive Health (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
前記組成物は、前記本発明の組成物である。
前記組成物は、前記本発明の組成物である。
前記組成物は、前記本発明の組成物である。
前記組成物は、前記本発明の組成物である。
本明細書において、「生体試料」は、生体に由来する試料であり、前記生体を構成する細胞を抽出または単離可能な試料を意味する。
ある態様において、本発明は、移植片拒絶反応が低減され、かつ生理活性を有する細胞由来の細胞外小胞またはそれを含む組成物を提供する。本発明の細胞外小胞は、生体試料由来の単核球から誘導された再生性細胞集団またはその培養物の細胞外小胞である。また、本発明の組成物は、生体試料由来の単核球から誘導された再生性細胞集団またはその培養物の細胞外小胞を含む。本発明の細胞外小胞または組成物は、前記移植片拒絶反応が抑制されており、かつ前記再生性細胞集団に由来するため、血管内皮細胞の増殖促進活性、血管新生促進活性等の生理活性を有する。このため、本発明の細胞外小胞または組成物は、例えば、後述のように、虚血性心疾患の治療または予後の改善に好適に使用できる。
(1)SCF、(2)IL-6、(3)FLT3L、(4)TPO、または(5)VEGF;
(6)SCFとIL-6との組合せ、(7)SCFとFLT3Lとの組合せ、(8)SCFとTPOとの組合せ、(9)SCFとVEGFとの組合せ、(10)IL-6とFLT3Lとの組合せ、(11)IL-6とTPOとの組合せ、(12)IL-6とVEGFとの組合せ、(13)FLT3LとTPOとの組合せ、(14)FLT3LとVEGFとの組合せ、または(15)TPOとVEGFとの組合せ;
(16)SCF、IL-6、およびFLT3Lの組合せ、(17)SCF、IL-6、およびTPOの組合せ、(18)SCF、FLT3L、およびTPOの組合せ、(19)SCF、FLT3L、およびVEGFの組合せ、(20)IL-6、FLT3L、およびTPOの組合せ、または(21)IL-6、FLT3L、およびVEGFの組合せ;
(22)SCF、IL-6、FLT3L、およびTPOの組合せ、(23)SCF、IL-6、FLT3L、およびVEGFの組合せ、または(24)IL-6、FLT3L、TPOおよびVEGFの組合せ;
(25)SCF、IL-6、FLT3L、TPOおよびVEGFの組合せ
別の態様において、本発明は、虚血性心疾患の処置に用いるための組成物またはそれを用いた方法を提供する。この場合、本発明は、虚血性心疾患の処置に用いるための組成物であって、前記組成物は、前記本発明の細胞外小胞または組成物である。また、本発明は、虚血性心疾患患者の処置方法であって、前記虚血性心疾患患者に、前記本発明の細胞外小胞または組成物を投与する。
本発明は、虚血性心疾患の治療に用いるための、細胞外小胞または組成物である。また、本発明は、血管内皮細胞の増殖促進に用いるための、細胞外小胞または組成物である。本発明は、血管新生の促進に用いるための、細胞外小胞または組成物である。本発明は、線維化抑制に用いるための、細胞外小胞または組成物である。
本発明の細胞外小胞が、血管内皮細胞増殖活性を有すること、血管新生促進活性を有すること、線維化抑制活性を有すること、および移植片拒絶反応が低減されていることを確認した。
再生性細胞集団は、ヒト末梢血単核球から誘導することにより調製した。まず、20~55歳の健康なボランティアから、50mlシリンジに装着されたヘパリン化翼状針を用いて末梢血を20~100ml採取した。前記採取に先立ち、各健常者へのインフォームドコンセントを行なった。また、前記採取は、東海大学医学部医学調査委員会の承認の下で行い、得られた末梢血サンプルの取り扱いは、ヒトサンプルに対する生物学的ガイドラインに沿って行った。また、以下に示す動物実験は、実験動物の取扱いガイドライン(National Research Council)に従い、東海大学医学部の動物実験委員会の承認を得て実施した。
rhSCF(Peprotech, Inc.社製、Cat. No. #300-07):100ng/ml
rhFlt3L(Peprotech, Inc.社製、Cat. No. #300-19):100ng/ml
rhTPO(Peprotech, Inc.社製、Cat. No. #300-18):20ng/ml
rhVEGF(Peprotech, Inc.社製、Cat. No. #100-02):50ng/ml
rhIL-6(Peprotech, Inc.社製、Cat. No. #200-06):20ng/ml
ペニシリン/ストレプトマイシン(Gibco社製)、Cat. No. 15140122:100U/100μg/ml)
r:組換え体
h:ヒト由来
前記培養後、前記RACを回収後、遠心した。得られたペレットを細胞外小胞産生培地に懸濁し、細胞懸濁液を調製した。前記細胞外小胞産生培地の組成は、エクソソーム除去済のウシ胎仔血清を5(v/v)%添加した、X-vivo 15培地(Lonza社製、Cat. No.BE02-054Q)とした。得られた細胞懸濁液を、10cmディッシュに、2.5×105細胞/ml/ディッシュ(250k)、または5×105細胞/ml/ディッシュ(500k)となるように播種後、48時間培養した。
前記実施例1(2)で調製した細胞外小胞について、その平均径、細胞あたりの産生量、およびマーカーの発現と、脂質膜および内腔の構造とを検討した。具体的には、平均径、細胞あたりの産生量、およびマーカーの発現は、フローサイトメトリー法により測定した。フローサイトメーターは、3レーザ(405nm、488nm、および638nm)を搭載するDxFlex Flow Cytometry(Beckman Coulter社製)について、以下の構成の変更を行なった上で使用した。405/10 VSSC フィルターは、WDM中のV450チャンネルに移動した。そして、ソフトウェア(CytExpert software)における検出器の構成を更新し、WDM内のVSSCチャネルに割り当てを行なった。また、各データの取得前に、前記フローサイトメーターの流路は、洗浄液(FlowClean)で洗浄後、10μmフィルターでろ過した水を通過させた。
RACevの血管内皮細胞の増殖促進活性は、ヒト胎児由来血管内皮細胞(HUVEC、Lonza社製、Cat. No.C2517A, Batch #. 18TL061650)を用いて検討した。具体的には、3~4回継代培養されたHUVECを回収後、Cytopainter dye(abcam社製、Cat. No. #ab176735)を添加して、37℃、10~30分間インキュベートすることにより、HUVEC細胞を標識した。前記標識後、遠心および洗浄を2回繰り返した。得られたHUVEC細胞について、3.5cmディッシュに5×104細胞/2ml/ディッシュとなるように播種した。前記HUVEC細胞の継代用培地は、EGM-2(Lonza社製)を用い、HUVEC細胞の増殖活性の測定用培地は、EBM-2(Lonza社製)を用いた。ついで、250kもしくは500kのRACまたはMSCから単離した細胞外小胞(RACevまたはMSCev)を各ディッシュに添加した。そして、前記培養条件で、2日間培養した。前記培養後、各ディッシュについて、位相差顕微鏡(6-well dish、Falcon社製)を用いて観察した。得られた位相差像において、一視野あたり(HPF)の細胞数をカウントし、さらに、全領域に対してHUVEC細胞が占める領域の割合を、成長領域として算出した。
虚血性心疾患においては、血管内皮細胞の増殖により、血管新生が生じると、予後が改善する。そこで、RACevが、虚血性心疾患の改善に寄与することを、ラット心筋梗塞モデルを確認した。具体的には、Lewisラット(雄、6~10週齢、体重150~250g、日本チャールズリバー社より購入)に対して挿管後、3~4%のセボフルラン(丸石製薬株式会社製)を15ml/kgで65~70分間吸入させることにより、麻酔下においた。左側開胸術後、左前下行枝(left anterior descending artery:LAD)について30分間虚血状態とした後に、再還流させることにより、虚血再灌流傷害を誘導した。前記誘導後、速やかに胸郭を閉じた。つぎに、500kのRACまたはMSCから単離した細胞外小胞(RACevまたはMSCev)をPBSで希釈し、得られた希釈液を、前記虚血再灌流傷害の誘導後の所定時間(30分後、1日後および2日後)に尾静脈から投与した。
%FS=(LVDD-LVDS)/LVDD×100 ・・・(1)
スコア3(重度):左心房壁に到達する逆流
スコア2(中程度):左心房の2/3に達する逆流
スコア1(軽度・軽微):左心房の1/3に達する逆流
前記虚血再灌流傷害による虚血性心疾患においては、線維化が生じる。そこで、RACevの投与により、線維化が抑制されるかを確認した。前記実施例1(5)の虚血再灌流傷害誘導4週後に、前記ラットから心臓を採取した。前記心臓に対して、1000U/mlのヘパリン含有PBSを用いて還流後、4%パラホルムアルデヒド(富士フイルム社製、Cat. No. #163-20145)で終夜(約8時間)固定した。前記固定後、前記心臓をパラフィンに包埋し、3~4μmの厚みのパラフィン包埋切片を調製した。前記切片について、ピクロシリウスレッドで染色後、一視野における間質線維化の占める割合(%)を決定した(Salybekov AA et.al., 2019, PLoS One 14: e0205477を参照)。コントロールは、RACevおよびMSCevを投与しなかった以外は同様にして実施した。また、HUVEC細胞の培養時に添加したRACevおよびMSCevについて、前記実施例1(4)と同様にして、各miRNA(miR-133a-3p、miR-133b、miR-29c-3p、miR-29b-3p)の相対的な発現量を算出した。これらの結果を、図9~図10に示す。なお、グラフ中の統計処理としては、Dunn's多重比較検定を実施した。
前記RACevの投与により、血管新生が促進するかを確認した。前記実施例1(6)で調製したパラフィン包埋切片について、アビジンおよびストレプトアビジン複合体でブロッキング後、100倍希釈したIsolectin B4-FITC(Invitrogen社製)および200倍希釈したαSMA-Cy3(Sigma社製)を用いて染色した。これにより、梗塞心筋の組織における微小血管および小動脈を染色した。得られた切片について、蛍光顕微鏡(FSX100、Olympus社製、HPF 20xで使用)または共焦点顕微鏡検査(LSM880、Carl Zeiss社製)を用いて観察した。また、得られた顕微鏡像から血管の密度を算出した。コントロールは、RACevおよびMSCevを投与しなかった以外は同様にして実施した。また、HUVEC細胞の培養時に添加したRACevおよびMSCevについて、前記実施例1(4)と同様にして、各miRNA(miR-126-3p、m miR-195-3p、miR-29c-3p、miR-126-5p、miR-15b-5p、miR-195-5p、miR-200b-5p、miR-146a-3p、miR-146-5p)の相対的な発現量を算出した。これらの結果を、図11~図12に示す。なお、グラフ中の統計処理としては、Dunn's多重比較検定を実施した。
RACevが虚血再灌流傷害の改善に寄与していることから、RACevは、in vivoにおいて、虚血再灌流で生じる炎症部位に集積していると推定される。そこで、RACevのHUVEC細胞への取り込み時間を検討した。具体的には、前記実施例1(2)で調製した標識化RACevについて、予めHUVEC細胞を播種したディッシュに添加し、経時的に標識を検出することによりRACevを検出した。この結果、添加後3~4時間において、HUVEC細胞内に取り込まれることがわかった。
前記RACevの投与後に、移植片拒絶反応が生じていないことを確認した。前記実施例1(5)と同様に、虚血再灌流傷害を誘導した。前記誘導後、速やかに胸郭を閉じた。つぎに、500kのRACまたはMSCから単離した細胞外小胞(RACevまたはMSCev)をPBSで希釈し、得られた希釈液を、前記虚血再灌流傷害の誘導後の所定時間(30分後、1日後および2日後)に尾静脈から投与した。そして、前記虚血再灌流傷害の誘導前(ベースライン)に初回の体重測定を実施し、その後、前記傷害の誘導後4週間まで週1回体重を測定した。また、前記誘導後4日および4週間において、脾臓を回収し、その重量を測定した。さらに、前記誘導後4週間において、末梢血および脾臓を回収した。そして、前記末梢血について、CD3陽性細胞、CD4陽性細胞、CD8陽性細胞、制御性T細胞およびCD11b/c陽性細胞の割合を、フローサイトメーターを用いて測定した。また、前記脾臓について、脾臓における移植片拒絶反応のマーカーであるCD3陽性細胞、CD4陽性細胞、CD8陽性細胞、TNK、iNKおよび抗原提示細胞と、制御性T細胞との割合を、フローサイトメーターを用いて測定した。コントロールは、RACevおよびMSCevを投与しなかった以外は同様にして実施した。また、投与したRACevおよびMSCevについて、前記実施例1(4)と同様にして、各miRNA(miR-142-3p)の相対的な発現量を算出したこれらの結果を図15~図18に示す。なお、グラフ中の統計処理としては、Dunn's多重比較検定を実施した。
末梢血単核球または臍帯血単核球を、各種因子で培養することにより、再生性細胞集団を誘導できることを確認した。
末梢血単核球は、前記実施例1(1)と同様にして調製した。また、前記末梢血に代えて、臍帯血を用いた以外は同様にして、臍帯血単核球を調製した。
・条件1:SS3G
無血清培地:StemSpan SFEM(Stemcell Technologies社製)
各因子:
rhSCF:100ng/ml
rhFlt3L:100ng/ml
rhTPO:20ng/ml
・条件2:SS5G
無血清培地:StemSpan SFEM
各因子:
rhSCF:100ng/ml
rhFlt3L:100ng/ml
rhTPO:20ng/ml
rhVEGF:50ng/ml
rhIL-6:20ng/ml
・条件3:SC3G
無血清培地:StemCell
各因子:
rhSCF:100ng/ml
rhFlt3L:100ng/ml
rhTPO:20ng/ml
・条件4:SC5G
無血清培地:StemCell
各因子:
rhSCF:100ng/ml
rhFlt3L:100ng/ml
rhTPO:20ng/ml
rhVEGF:50ng/ml
rhIL-6:20ng/ml
・条件5:SC3G
無血清培地:Stemline(SIGMA社製)
各因子:
rhSCF:100ng/ml
rhFlt3L:100ng/ml
rhTPO:20ng/ml
・条件6:SL5G
無血清培地:Stemline
各因子:
rhSCF:100ng/ml
rhFlt3L:100ng/ml
rhTPO:20ng/ml
rhVEGF:50ng/ml
rhIL-6:20ng/ml
再生性細胞集団の血管形成能を調べるため、EPCコロニー形成アッセイ(EPC-CFA)により接着性EPCコロニーを定量した。EPC-CFAは、Masuda H. et al., Circulation research, 109: 20-37 (2011)に記載の方法に準じて行った。具体的には、35mm Primaria(商標)dish(BD Falcon社製)を用いて、半固形培地中で、各細胞を16~18日間培養した。前記半固形培地の組成は、下記表1とした。前記培養後、位相差光学顕微鏡(Eclipse TE300、Nikon社製)を用いて、ディッシュあたりの接着性コロニー数をgridded scoring dish (Stem Cell Tec社製)を用いて測定した。未分化型EPCコロニー(SEPC-CFU (primitive EPC colony forming unit))と分化型EPCコロニー(DEPC-CFU (definitive EPC colony forming unit))とを別々にカウントした。コントロール(pre)は、前記再生性細胞集団に代えて、前記末梢血単核球または前記臍帯血単核球を用いた以外は同様にして実施した。これらの結果を図20に示す。
[実施例3]
本発明の臍帯由来の細胞外小胞が、血管新生促進活性を有するmiRNA、抗アポトーシス活性を有するmiRNA、抗線維化活性を有するmiRNA、抗線維化活性を有するmiRNA、および細胞増殖促進活性を有するmiRNAを含むことを確認した。
臍帯由来の再生性細胞集団は、ヒト臍帯血由来単核細胞、またはヒト臍帯血由来CD34陽性前駆細胞から誘導することにより調製した。まず、ヒト臍帯血由来単核細胞(以下、「CBMCs」、タカラバイオ株式会社社製)およびヒト臍帯血由来CD34陽性血管内皮前駆細胞(以下、「CD34細胞」、タカラバイオ株式会社社製)を、QQ培地を用いて培養した。QQ培地による培養は、実施例1(1)に記載の方法を用いて行った。
前記培養後、前記CBMCsまたはCD34細胞を回収後、細胞外小胞産生培地に懸濁し、細胞懸濁液を調製した。前記細胞外小胞産生培地の組成は、エクソソーム除去済のウシ胎仔血清を5(v/v)%を添加した、X-vivo 15(Lonza社製、Cat. No.BE02-054Q)とした。前記調製後、48時間培養した。
臍帯血由来の単核細胞の細胞外小胞(CB-MNCev)、およびMSC由来の細胞外小胞MSCevについて、miRNAの分析を行なった。具体的には、実施例1(4)と同様の方法で行った。得られたシーケンスデータから、各miRNA(miR-17-3p、miR-20b-5p、miR-92a-3p、miR-103a-2-5p、miR-126b-3p、miR-144-5p、miR-148a-3p、miR-181b-3p、miR-200a-3p、miR-205-5p、miR-373-3p、miR-509-3p、miR-633)の相対的な発現量を算出した。これらの結果を、図21に示す。なお、グラフ中の統計処理としては、Two-way ANOVA検定後に、テューキーの多重比較検定を実施した。
つぎに、臍帯血由来のCD34陽性血管内皮前駆細胞の細胞外小胞(CB-CD34ev)、およびMSC由来の細胞外小胞MSCevについて、、miRNAの分析を行なった。具体的には、実施例1(4)と同様の方法で行った。得られたシーケンスデータから、各miRNA(miR-10a-3p、miR-17-3p、miR-20b-5p、miR-21-5p、miR-24-2-5p、miR-29a-5p、miR-29c-3p、miR-30b-5p、miR-30c-5p、miR-30e-3p、miR-30e-5p、miR-32-5p、miR-126-3p、miR-126-5p、miR-133a-3p、miR-133b、miR-199b-5p、miR-210-3p、miR-221-5p、miR-324-5p、miR-363-3p、let-7c-5p)の相対的な発現量を算出した。これらの結果を、図22に示す。なお、グラフ中の統計処理としては、Two-way ANOVA検定後に、テューキーの多重比較検定を実施した。
上記の実施形態および実施例の一部または全部は、以下の付記のように記載されうるが、以下には限られない。
<組成物>
(付記1)
生体試料由来の単核球から誘導された再生性細胞集団またはその培養物の細胞外小胞を含む、組成物。
(付記2)
前記細胞外小胞は、miR-15b-5p、miR-29b-3p、miR-29c-3p、miR-92a-2-5p、miR-126-3p、miR-126-5p、miR-133a-3p、miR-133b、miR-146a-3p、miR-146b-5p、miR-150-5p、miR-181b-3p、miR-195-3p、miR-195-5p、miR-200b-5p、miR-302a-5p、および/またはmiR-142-3pを含む、付記1に記載の組成物。
(付記3)
さらに、前記細胞外小胞は、miR-10a-3p、miR-17-3p、miR-20b-5p、miR-21-5p、miR-24-2-5p、miR-29a-5p、miR-30b-5p、miR-30c-5p、miR-30e-3p、miR-30e-5p、miR-32-5p、miR-92a-3p、miR-103a-2-5p、miR-144-5p、miR-148a-3p、miR-199b-5p、miR-200a-3p、miR-205-5p、miR-210-3p、miR-221-5p、miR-324-5p、miR-363-3p、miR-373-3p、miR-509-3p、miR-633、および/またはlet-7c-5pを含む付記1または2に記載の組成物。
(付記4)
前記細胞外小胞は、CD9および/またはCD63陽性である、付記1から3のいずれかに記載の組成物。
(付記5)
前記細胞外小胞の平均径は、10~500nmである、付記1から4のいずれかに記載の組成物。
(付記6)
血管内皮細胞の増殖促進活性を有する、付記1から5のいずれかに記載の組成物。
(付記7)
血管新生促進活性を有する、付記1から6のいずれかに記載の組成物。
(付記8)
線維化抑制活性を有する、付記1から7のいずれかに記載の組成物。
(付記9)
移植片拒絶反応が抑制された、付記1から8のいずれかに記載の組成物。
(付記10)
前記細胞外小胞は、前記再生性細胞集団またはその培養物から、抽出または単離された細胞外小胞である、付記1から9のいずれかに記載の組成物。
(付記11)
前記再生性細胞集団は、前記単核球を、幹細胞因子、インターロイキン6、FMS様チロシンキナーゼ3リガンド、トロンボポエチン、および/または血管内皮細胞増殖因子の存在下、培養することで誘導される、付記1から10のいずれかに記載の組成物。
(付記12)
前記再生性細胞集団は、CD34および/またはCD133陽性細胞の選別を行うことなく誘導される、付記1から11のいずれかに記載の組成物。
(付記13)
前記再生性細胞集団は、血管内皮前駆細胞および抗炎症性マクロファージを含む、付記1から12のいずれかに記載の組成物。
(付記14)
前記血管内皮前駆細胞は、分化型EPCコロニー形成細胞である、付記13に記載の組成物。
(付記15)
抗炎症性マクロファージは、M2マクロファージである、付記13または14に記載の組成物。
(付記16)
前記生体試料は、血液および骨髄の少なくとも一方である、付記1から15のいずれかに記載の組成物。
(付記17)
前記生体試料は、末梢血および臍帯血の少なくとも一方である、付記1から16のいずれかに記載の組成物。
<虚血性心疾患の処置組成物>
(付記18)
虚血性心疾患の処置に用いるための組成物であって、
前記組成物は、付記1から17のいずれかに記載の組成物である、組成物。
(付記19)
前記虚血性心疾患は、心筋梗塞である、付記18に記載の組成物。
<血管内皮細胞の増殖促進組成物>
(付記20)
血管内皮細胞の増殖促進に用いるための組成物であって、
前記組成物は、付記1から17のいずれかに記載の組成物である、組成物。
<血管新生誘導組成物>
(付記21)
血管新生の誘導に用いるための組成物であって、
前記組成物は、付記1から17のいずれかに記載の組成物である、組成物。
<線維化抑制組成物>
(付記22)
線維化の抑制に用いるための組成物であって、
前記組成物は、付記1から17のいずれかに記載の組成物である、組成物。
<虚血性心疾患の処置方法>
(付記23)
虚血性心疾患患者の処置方法であって、
前記虚血性心疾患患者に、付記1から17のいずれかに記載の組成物を投与する、処置方法。
(付記24)
前記虚血性心疾患は、心筋梗塞、末梢動脈疾患、心筋虚血再灌流障害、または重症下肢虚血である、付記23に記載の処置方法。
<血管内皮細胞の増殖促進方法>
(付記25)
血管内皮細胞の増殖促進方法であって、
前記血管内皮細胞と、組成物とを接触させることにより、前記血管内皮細胞の増殖を促進する工程を含み、
前記組成物は、付記1から17のいずれかに記載の組成物である、方法。
<血管新生の誘導方法>
(付記26)
血管新生の誘導方法であって、
付記1から17のいずれかに記載の組成物を使用する、方法。
(付記27)
血管新生を誘導する対象に、前記組成物を投与する、付記26に記載の方法。
(付記28)
血管新生を誘導する対象は、虚血性心疾患患者であり、
前記血管新生の誘導は、前記虚血性心疾患患者の心臓における血管新生の誘導である、付記27または28に記載の方法。
<線維化抑制方法>
(付記29)
線維化の抑制方法であって、
付記1から17のいずれかに記載の組成物を使用する、方法。
(付記30)
線維化を抑制する対象に、前記組成物を投与する、付記29に記載の方法。
(付記31)
線維化を抑制する対象は、虚血性心疾患患者であり、
前記線維化の抑制は、前記虚血性心疾患患者の心臓における線維化の抑制である、付記29または30に記載の方法。
<使用>
(付記32)
虚血性心疾患の処置に使用するための組成物であり、
前記組成物は、付記1から17のいずれかに記載の組成物。
(付記33)
血管内皮細胞の増殖促進に使用するための組成物であり、
前記組成物は、付記1から17のいずれかに記載の組成物。
(付記34)
血管新生の誘導に使用するための組成物であり、
前記組成物は、付記1から17のいずれかに記載の組成物。
(付記35)
線維化の抑制に使用するための組成物であり、
前記組成物は、付記1から17のいずれかに記載の組成物。
Claims (22)
- 生体試料由来の単核球から誘導された再生性細胞集団またはその培養物の細胞外小胞を含む、組成物。
- 前記細胞外小胞は、miR-15b-5p、miR-29b-3p、miR-29c-3p、miR-92a-2-5p、miR-126-3p、miR-126-5p、miR-133a-3p、miR-133b、miR-146a-3p、miR-146b-5p、miR-150-5p、miR-181b-3p、miR-195-3p、miR-195-5p、miR-200b-5p、miR-302a-5p、および/またはmiR-142-3pを含む、請求項1に記載の組成物。
- さらに、前記細胞外小胞は、miR-10a-3p、miR-17-3p、miR-20b-5p、miR-21-5p、miR-24-2-5p、miR-29a-5p、miR-30b-5p、miR-30c-5p、miR-30e-3p、miR-30e-5p、miR-32-5p、miR-92a-3p、miR-103a-2-5p、miR-144-5p、miR-148a-3p、miR-199b-5p、miR-200a-3p、miR-205-5p、miR-210-3p、miR-221-5p、miR-324-5p、miR-363-3p、miR-373-3p、miR-509-3p、miR-633、および/またはlet-7c-5pを含む請求項2に記載の組成物。
- 前記細胞外小胞は、CD9および/またはCD63陽性である、請求項1から3のいずれか一項に記載の組成物。
- 前記細胞外小胞の平均径は、10~500nmである、請求項1から4のいずれか一項に記載の組成物。
- 血管内皮細胞の増殖促進活性を有する、請求項1から5のいずれか一項に記載の組成物。
- 血管新生促進活性を有する、請求項1から6のいずれか一項に記載の組成物。
- 線維化抑制活性を有する、請求項1から7のいずれか一項に記載の組成物。
- 移植片拒絶反応が抑制された、請求項1から8のいずれか一項に記載の組成物。
- 前記細胞外小胞は、前記再生性細胞集団またはその培養物から、抽出または単離された細胞外小胞である、請求項1から9のいずれか一項に記載の組成物。
- 前記再生性細胞集団は、前記単核球を、幹細胞因子、インターロイキン6、FMS様チロシンキナーゼ3リガンド、トロンボポエチン、および/または血管内皮細胞増殖因子の存在下、培養することで誘導される、請求項1から10のいずれか一項に記載の組成物。
- 前記再生性細胞集団は、CD34および/またはCD133陽性細胞の選別を行うことなく誘導される、請求項1から11のいずれか一項に記載の組成物。
- 前記再生性細胞集団は、血管内皮前駆細胞および抗炎症性マクロファージを含む、請求項1から12のいずれか一項に記載の組成物。
- 前記血管内皮前駆細胞は、分化型EPCコロニー形成細胞である、請求項13に記載の組成物。
- 抗炎症性マクロファージは、M2マクロファージである、請求項12または14に記載の組成物。
- 前記生体試料は、血液および骨髄の少なくとも一方である、請求項1から15のいずれか一項に記載の組成物。
- 前記生体試料は、末梢血および臍帯血の少なくとも一方である、請求項1から16のいずれか一項に記載の組成物。
- 虚血性心疾患の処置に用いるための組成物であって、
前記組成物は、請求項1から17のいずれか一項に記載の組成物である、組成物。 - 前記虚血性心疾患は、心筋梗塞、末梢動脈疾患、心筋虚血再灌流障害、または重症下肢虚血である、請求項18に記載の組成物。
- 血管内皮細胞の増殖促進に用いるための組成物であって、
前記組成物は、請求項1から17のいずれか一項に記載の組成物である、組成物。 - 血管新生の誘導に用いるための組成物であって、
前記組成物は、請求項1から17のいずれか一項に記載の組成物である、組成物。 - 線維化の抑制に用いるための組成物であって、
前記組成物は、請求項1から17のいずれか一項に記載の組成物である、組成物。
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP22807560.2A EP4331592A1 (en) | 2021-05-13 | 2022-05-13 | Composition and use thereof |
JP2023521263A JPWO2022239862A1 (ja) | 2021-05-13 | 2022-05-13 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2021081426 | 2021-05-13 | ||
JP2021-081426 | 2021-05-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022239862A1 true WO2022239862A1 (ja) | 2022-11-17 |
Family
ID=84028377
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2022/020222 WO2022239862A1 (ja) | 2021-05-13 | 2022-05-13 | 組成物およびその用途 |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP4331592A1 (ja) |
JP (1) | JPWO2022239862A1 (ja) |
WO (1) | WO2022239862A1 (ja) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2011529957A (ja) | 2008-08-04 | 2011-12-15 | セレリックス エスエー | 間葉系幹細胞の使用 |
WO2014051154A1 (ja) | 2012-09-28 | 2014-04-03 | 公益財団法人先端医療振興財団 | 虚血性疾患治療に適した細胞を含む細胞群の生体外増幅方法 |
CN111249293A (zh) * | 2020-03-13 | 2020-06-09 | 湖南中医药大学第一附属医院((中医临床研究所)) | 黄芪甲苷在制备促进血管新生药物中的应用 |
US20200390822A1 (en) * | 2018-02-27 | 2020-12-17 | Musc Foundation For Research Development | Compositions and methods for treating and/or preventing sepsis and/or inflammatory conditions |
JP2021081426A (ja) | 2019-11-21 | 2021-05-27 | メコ・エス アー | 腕時計補正器および腕時計胴部 |
-
2022
- 2022-05-13 JP JP2023521263A patent/JPWO2022239862A1/ja active Pending
- 2022-05-13 EP EP22807560.2A patent/EP4331592A1/en active Pending
- 2022-05-13 WO PCT/JP2022/020222 patent/WO2022239862A1/ja active Application Filing
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2011529957A (ja) | 2008-08-04 | 2011-12-15 | セレリックス エスエー | 間葉系幹細胞の使用 |
WO2014051154A1 (ja) | 2012-09-28 | 2014-04-03 | 公益財団法人先端医療振興財団 | 虚血性疾患治療に適した細胞を含む細胞群の生体外増幅方法 |
US20200390822A1 (en) * | 2018-02-27 | 2020-12-17 | Musc Foundation For Research Development | Compositions and methods for treating and/or preventing sepsis and/or inflammatory conditions |
JP2021081426A (ja) | 2019-11-21 | 2021-05-27 | メコ・エス アー | 腕時計補正器および腕時計胴部 |
CN111249293A (zh) * | 2020-03-13 | 2020-06-09 | 湖南中医药大学第一附属医院((中医临床研究所)) | 黄芪甲苷在制备促进血管新生药物中的应用 |
Non-Patent Citations (5)
Title |
---|
AMANKELDI, PLOSONE, vol. 14, no. 3, 2019, pages e0205477 |
ASAHARA ET AL., SCIENCE, vol. 275, 1997, pages 964 - 7 |
MASUDA H. ET AL., CIRCULATION RESEARCH, vol. 109, 2011, pages 20 - 37 |
SALYBEKOV AMANKELDI A., KAWAGUCHI AKIRA T., MASUDA HARUCHIKA, VORATEERA KOSIT, OKADA CHISA, ASAHARA TAKAYUKI: "Regeneration-associated cells improve recovery from myocardial infarction through enhanced vasculogenesis, anti-inflammation, and cardiomyogenesis", PLOS ONE, vol. 13, no. 11, 28 November 2018 (2018-11-28), pages e0203244, XP055801358, DOI: 10.1371/journal.pone.0203244 * |
SALYBEKOV AMANKELDI A., SALYBEKOVA AINUR, SHENG YIN, SHINOZAKI YOSHIKO, YOKOYAMA KEIKO, KOBAYASHI SHUZO, ASAHARA TAKAYUKI: "Extracellular Vesicles Derived From Regeneration Associated Cells Preserve Heart Function After Ischemia-Induced Injury", FRONTIERS IN CARDIOVASCULAR MEDICINE, vol. 8, 1 January 2021 (2021-01-01), pages 754254, XP093003212, DOI: 10.3389/fcvm.2021.754254 * |
Also Published As
Publication number | Publication date |
---|---|
JPWO2022239862A1 (ja) | 2022-11-17 |
EP4331592A1 (en) | 2024-03-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6709834B2 (ja) | プロスタサイクリンおよび間葉系幹細胞による脈管障害の処置 | |
US10787641B2 (en) | Therapeutic use of CD31 expressing cells | |
JP5968442B2 (ja) | 心筋梗塞の修復再生を誘導する多能性幹細胞 | |
JP6682090B2 (ja) | 虚血性疾患治療に適した細胞を含む細胞群の生体外増幅方法 | |
JP6571537B2 (ja) | 療法および予防のための細胞を単離する方法 | |
JP2021520790A (ja) | 細胞型特異的エキソソームおよびそれらの使用 | |
JP7249951B2 (ja) | 標的臓器の細胞外構成成分を使用する治療用細胞の作製 | |
JP2016128521A (ja) | 虚血組織の細胞療法 | |
US20100158874A1 (en) | Compositions and Methods for Treating Peripheral Vascular Diseases | |
WO2022239862A1 (ja) | 組成物およびその用途 | |
US11963983B2 (en) | Methods of cardiac repair | |
WO2024101047A1 (ja) | 組成物およびその用途 | |
WO2018196566A1 (zh) | Vcam-1+单核细胞及其衍生细胞在促进造血干细胞归巢的应用 | |
US20230034582A1 (en) | Cell population and method of obtaining the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22807560 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2023521263 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 18560266 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2023/0765.1 Country of ref document: KZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2022807560 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2022807560 Country of ref document: EP Effective date: 20231201 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |